INTERIM FINANCIAL STATEMENTS

FOR THE FIRST 6 MONTHS
OF THE FISCAL YEAR ENDING 31 DECEMBER 2026

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM

Digitally signed by CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM
Date: 2026.08.14 14:06:43 +07'00'

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

CONTENTS

****

GENERAL INFORMATION

Corporate information

Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") is a joint stock company operating under Business Registration Certificate No. 1600699279, first registered on 3 June 2004 and amended for the 22nd time on 21 June 2026 by the An Giang Province Department of Finance.

Principal business activities of the Company are to manufacture medicines, pharmaceutical chemicals and pharmaceutical materials; trade optical, medical, dental and hospital equipment; trade medicines and pharmaceutical products; trade nutritious food; manufacture and trade cosmetics; trade materials and ancillary materials, pharmaceutical chemicals for pharmaceutical production; trade vaccines and medical biological products; manufacture bottled and jarred drinking water (the Company must comply with the Law on food safety and hygiene during operation course); manufacture dietary supplements; manufacture, trade and process essential oil from herbs; manufacture and trade food, nutritious food and dietary supplements.

Head office

- Address : No. 27 Nguyen Thai Hoc, Long Xuyen Ward, An Giang Province, Vietnam
- Telephone : (0296) 385 6961–385 6964
- Fax : (0296) 385 7301

The company has the following affiliates:

Affiliate	Address
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 49-51-53, Street No. 3A, An Lac Ward, Ho Chi Minh City
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 42 Nguyen Sinh Sac Street, Hoa Khanh Ward, Da Nang City
Branch of Agimexpharm Pharmaceutical Joint Stock Company - Agimexpharm Pharmaceutical Manufacturing Factory	No. 66 Vu Trong Phung Street, Thanh An Cluster, My Thoi Ward, An Giang Province
Branch of Agimexpharm Pharmaceutical Joint Stock Company – Binh Hoa Factory	Lot C4, Binh Hoa Industrial Park, Binh Hoa Commune, An Giang Province
Agimexpharm Pharmaceutical Joint Stock Company – Tay Nguyen Branch	No. 184/84 Giai Phong Street, Buon Ma Thuot Ward, Dak Lak Province
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 46, Lane 105, Lang Ha Street, Dong Da Ward, Hanoi City

Board of Directors

The members of the Board of Directors during the period and up to the date of this report are as follows:

Full name	Position	Appointing/re-appointing date
Ms. Pham Thi Bich Thuy	Chairwoman	Reappointed on 8 April 2023
Mr. Nguyen Van Kha	Vice Chairman	Reappointed on 8 April 2023
Ms. Tran Thi Dao	Member	Reappointed on 8 April 2023
Mr. Nguyen Quoc Dinh	Member	Reappointed on 8 April 2023
Mr. Pham Uyen Nguyen	Member	Reappointed on 8 April 2023
Mr. Huynh Hoang Ha	Member	Appointed on 8 April 2023

The **Supervisory Board**

The members of the Supervisory Board during the period and up to the date of this report are as follows:

Full name	Position	Appointing/re-appointing/resigned date
Ms. Tran Thi Thanh Hang	Chief of the Board	Reappointed on 8 April 2023
Ms. Nguyen Hong Ngoc	Member	Reappointed on 8 April 2023
Ms. Nguyen Thi An	Member	Appointed on 27 March 2026
Ms. Pham Hai Yen	Member	Appointed on 8 April 2023 Resigned on 27 March 2026

Board of Management

The members of the Board of Management during the period and up to the date of this report are as follows:

Full name	Position	Appointing/re-appointing date
Mr. Nguyen Van Kha	General Director	Reappointed on 8 April 2023
Ms. Pham Thi Bich Thuy	Deputy General Director	Appointed on 2 January 2018
Mr. Lam Tri Hien	Deputy General Director	Appointed on 22 February 2019
Mr. Vu Minh Tuan	Deputy General Director	Appointed on 1 October 2019
Mr. Huynh Hoang Ha	Deputy General Director	Appointed on 1 January 2021
Mr. Le Van Mac	Deputy General Director	Appointed on 25 May 2026

Legal Representative

The Company's legal representative during the period and up to the date of this report is Mr. Nguyen Van Kha – General Director (reappointed on 8 April 2023).

Auditors

A&C Auditing and Consulting Co., Ltd. has been appointed to perform the Company's Interim Financial Statements for the first 6 months of the fiscal year ending 31 December 2026.

STATEMENT OF THE BOARD OF MANAGEMENT

The Board of Management of Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as the "Company") hereby submits its report together with the Interim Financial Statements for the first six months of the fiscal year ending 31 December 2026.

Responsibility of the Board of Management

The Board of Management is responsible for the preparation of the Interim Financial Statements to give a true and fair view of the financial position, the financial performance and the cash flows of the Company during the period. In order to prepare these Interim Financial Statements, the Board of Management must:

- select appropriate accounting policies and apply them consistently;
- make judgments and estimates reasonably and prudently;
- state whether applicable accounting standards have been followed or not, and all the differences subject to any material departures are disclosed and explained in the Interim Financial Statements;
- prepare the Interim Financial Statements of the Company on a going-concern basis unless it is inappropriate to presume that the Company will continue in business;
- design and implement effectively the internal control system to minimize the risks of material misstatements due to fraud or error in the preparation and presentation of the Interim Financial Statements.

The Board of Management hereby ensures that all the proper accounting books of the Company have been fully recorded that disclose with reasonable accuracy at any time the financial position of the Company, and that all the accounting books have been prepared in accordance with the applicable Accounting System. The Board of Management is also responsible for safeguarding the Company's assets and consequently has taken appropriate measures to prevent and detect fraud and other irregularities.

The Board of Management hereby confirms that the Company has complied with the aforementioned requirements in the preparation of the Interim Financial Statements.

Statement of the Board of Management

In the opinion of the Board of Management, the Interim Financial Statements give a true and fair view of the financial position of the Company as of 30 June 2026 and of its financial performance and cash flows for the first 6 months of the fiscal year ending 31 December 2026, in accordance with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, and relevant statutory requirements on the preparation and presentation of the Interim Financial Statements.

For and on behalf of the Board of Management,

Nguyen Van Kha
General Director

Date: 12 August 2026

A&C AUDITING AND CONSULTING CO., LTD.

bakertilly A&C

Ho Chi Minh Head Office : 02 Truong Son St., Tan Son Hoa Ward, Ho Chi Minh City, Vietnam Tel: +84 (028) 3547 2972 kttv@a-c.com.vn
Hanoi Branch : 40 Giang Vo St., Giang Vo Ward, Ha Noi City, Vietnam Tel: +84 (024) 3736 7879 kttv.hn@a-c.com.vn
Central Region Branch : Lot STH 06A.01, Road 13, Le Hong Phong II Urban Area, Nam Nha Trang Ward, Khanh Hoa Province, Vietnam Tel: +84 (0258) 246 5151 kttv.nt@a-c.com.vn
Southwest Branch : I5-13 Vo Nguyen Giap St., Hung Phu Ward, Can Tho City, Vietnam Tel: +84 (0292) 376 4995 kttv.ct@a-c.com.vn

www.a-c.com.vn

No. 4.0272/26/TC-AC

REPORT ON THE REVIEW OF INTERIM FINANCIAL STATEMENTS

To: **SHAREHOLDERS, THE BOARD OF DIRECTORS AND THE BOARD OF MANAGEMENT**
AGIMEXPHARM PHARMACEUTICALS JOINT STOCK COMPANY

We have reviewed the accompanying Interim Financial Statements of Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company"), which were prepared on 12 August 2026, from page 06 to page 54, including the Interim Statement of Financial Position as of 30 June 2026, the Interim Income Statement, the Interim Cash Flow Statement for the first 6 months of the fiscal year ending 31 December 2026, and the Notes to the Interim Financial Statements.

Responsibility of the Board of Management

The Board of Management is responsible for the preparation, true and fair presentation of the Company's Interim Financial Statements in accordance with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System and relevant statutory requirements on the preparation and presentation of the Interim Financial Statements; and responsible for such internal control as the Company's Board of Management determines necessary to enable the preparation and presentation of the Interim Financial Statements to be free from material misstatement due to fraud or error.

Responsibility of Auditors

Our responsibility is to express a conclusion on the Interim Financial Statements based on our review. We have conducted the review in accordance with the Vietnamese Standards on Review Engagements No. 2410 – Review of Interim Financial Information Prepared by the Entity's Independent Auditor.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion of Auditors

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Financial Statements do not give a true and fair view, in all material respects, of the financial position of Agimexpharm Pharmaceutical Joint Stock Company as of 30 June 2026, its financial performance and its cash flows for the first 6 months of the fiscal year ending 31 December 2026, in accordance with Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System and relevant statutory requirements on the preparation and presentation of Interim Financial Statements.

A&C Auditing and Consulting Co., Ltd.
Southwest Branch

A&C
CHI NHÁNH
TÂY NAM BỘ

Nguyen Huu Danh - Partner
Audit Practice Registration Certificate No. 1242-2023-008-1
Authorized Signatory

Can Tho City, on 12 August 2026

INTERIM STATEMENT OF FINANCIAL POSITION

(Full form)
As at 30 June 2026

Unit: VND

ITEMS	Code	Notes	Ending balance	Beginning balance
A - CURRENT ASSETS	**100**		**758.398.165.325**	**777.726.903.970**
I. Cash and cash equivalents	**110**	**V.1**	**43.539.643.614**	**73.077.662.081**
1. Cash	111		37.530.273.751	27.089.251.455
2. Cash equivalents	112		6.009.369.863	45.988.410.626
II. Short-term financial investments	**120**		**6.289.240.297**	**6.185.678.653**
1. Trading securities	121	V.2a	1.097.651.256	1.097.651.256
2. Provisions for devaluation of trading securities	122		-	-
3. Short-term held-to-maturity investments	123	V.2b	5.191.589.041	5.088.027.397
4. Provisions for impairment of short-term held-to-maturity investments	124		-	-
5. Other short-term investments	125		-	-
6. Provisions for impairment of other short-term investments	126		-	-
III. Short-term receivables	**130**		**315.347.831.514**	**234.716.627.353**
1. Short-term trade receivables	131	V.3	184.318.875.914	154.328.616.775
2. Short-term advances to suppliers	132	V.4	11.758.823.428	5.973.546.025
3. Short-term intra-company receivables	133		-	-
4. Receivables from construction contracts under percentage of completic	134		-	-
5. Other short-term receivables	135	V.5a	124.266.205.109	79.015.183.426
6. Allowance for short-term doubtful debts	136	V.6	(4.996.072.937)	(4.600.718.873)
7. Shortage of assets awaiting resolution	137		-	-
IV. Inventories	**140**		**370.901.850.586**	**341.450.986.601**
1. Inventories	141	V.7	370.901.850.586	341.450.986.601
2. Allowance for devaluation of inventories	142		-	-
V. Current biological assets	**150**		**-**	**-**
1. Short-term livestock intended for one-time harvest	151		-	-
2. Short-term seasonal or one-time harvest crops	152		-	-
3. Provisions for impairment of current biological assets	153		-	-
VI. Other current assets	**160**		**22.319.599.314**	**122.295.949.282**
1. Short-term deferred expenses	161	V.8a	551.929.939	703.417.818
2. Deductible VAT	162		21.460.558.704	23.020.588.406
3. Taxes and other receivables from the State	163	V.17	307.110.671	167.552.491
4. Trading Government bonds	164		-	-
5. Other current assets	165	V.9	-	98.404.390.567

Interim Statement of Financial Position (cont.)

ITEMS	Code	Notes	Ending balance	Beginning balance
B- NON-CURRENT ASSETS	**200**		**704.210.882.573**	**585.933.358.989**
I. Long-term receivables	**210**		**43.115.227.680**	**23.772.155.478**
1. Long-term trade receivables	211		-	-
2. Long-term advances to suppliers	212		-	-
3. Working capital in affiliates	213		-	-
4. Long-term intra-company receivables	214		-	-
5. Other long-term receivables	215	V.5b	43.115.227.680	23.772.155.478
6. Allowance for long-term doubtful debts	216		-	-
II. Fixed assets	**220**		**413.345.509.390**	**401.716.726.273**
1. Tangible fixed assets	221	V.10	315.854.563.416	321.849.395.361
- *Historical cost*	*222*		*508.188.468.539*	*502.428.649.474*
- *Accumulated depreciation*	*223*		*(192.333.905.123)*	*(180.579.254.113)*
2. Financial leased assets	224	V.11	79.361.104.603	61.718.901.019
- *Historical cost*	*225*		*91.339.688.919*	*68.420.125.038*
- *Accumulated depreciation*	*226*		*(11.978.584.316)*	*(6.701.224.019)*
3. Intangible fixed assets	227	V.12	18.129.841.371	18.148.429.893
- *Historical cost*	*228*		*20.510.164.376*	*20.510.164.376*
- *Accumulated depreciation*	*229*		*(2.380.323.005)*	*(2.361.734.483)*
III. Non-current biological assets	**230**		-	-
1. Bearer animals	231		-	-
a) Immature bearer animals	232		-	-
b) Mature bearer animals	233		-	-
- *Historical cost*	*234*		-	-
- *Accumulated depreciation*	*235*		-	-
2. Long-term livestock intended for one-time harvest	236		-	-
3. Long-term seasonal or one-time harvest crops	237		-	-
4. Provisions for impairment of non-current biological assets	238		-	-
IV. Investment property	**240**		-	-
- Historical cost	241		-	-
- Accumulated depreciation	242		-	-
V. Non-current assets in process	**250**		**212.723.331.237**	**125.438.110.860**
1. Long-term work in process	251		-	-
2. Construction in progress	252	V.13	212.723.331.237	125.438.110.860
VI. Long-term financial investments	**260**		**17.130.750.000**	**17.130.750.000**
1. Investments in subsidiaries	261		-	-
2. Investments in joint ventures and associates	262	V.2c	17.130.750.000	17.130.750.000
3. Equity investments in other entities	263		-	-
4. Provisions for impairment of long-term investments in other entities	264		-	-
5. Long-term held-to-maturity investments	265		-	-
6. Provisions for impairment of long-term held-to-maturity investments	266		-	-
VI. Other non-current assets	**270**		**17.896.064.266**	**17.875.616.378**
1. Long-term deferred expenses	271	V.8b	17.896.064.266	17.875.616.378
2. Deferred income tax assets	272		-	-
3. Long-term components and spare parts	273		-	-
4. Other non-current assets	278		-	-
TOTAL ASSETS	**280**		**1.462.609.047.898**	**1.363.660.262.959**

Interim Statement of Financial Position (cont.)

ITEMS	Code	Notes	Ending balance	Beginning balance
C - LIABILITIES	**300**		**857.868.713.077**	**909.239.635.478**
I. Current liabilities	**310**		**655.657.508.603**	**792.607.200.373**
1. Short-term trade payables	311	V.14	156.257.757.371	93.879.304.480
2. Short-term advances from customers	312	V.15	7.710.516.798	9.460.079.631
3. Payables for dividends and profit distributions	313	V.16	267.381.200	267.381.200
4. Short-term taxes and amounts payable to the State budget	314	V.17	5.847.796.351	13.578.767.542
5. Payables to employees	315		-	-
6. Short-term accrued expenses	316	V.18	845.299.074	1.570.510.420
7. Short-term intra-company payables	317		-	-
8. Short-term payables relating to construction contracts under percentage	318		-	-
9. Short-term deferred revenue	319	V.19	1.631.394.056	4.172.755.675
10. Other short-term payables	320	V.20	8.417.849.276	142.480.298.392
11. Short-term borrowings and financial lease liabilities	321	V.21a	473.277.553.716	515.594.422.349
12. Provisions for short-term payables	322		-	-
13. Bonus and welfare fund	323	V.22	1.401.960.761	11.603.680.684
14. Price stabilization fund	324		-	-
15. Trading Government bonds	325		-	-
II. Non-current liabilities	**330**		**202.211.204.474**	**116.632.435.105**
1. Long-term trade payables	331		-	-
2. Long-term advances from customers	332		-	-
3. Long-term taxes and amounts payable to the State budget	333		-	-
4. Long-term accrued expenses	334		-	-
5. Intra-company payables for working capital received	335		-	-
6. Long-term intra-company payables	336		-	-
7. Long-term deferred revenue	337	V.19	3.102.913.811	-
8. Other long-term payables	338		-	-
9. Long-term borrowings and financial lease liabilities	339	V.21b	199.108.290.663	116.632.435.105
10. Convertible bonds	340		-	-
11. Preferred shares	341		-	-
12. Deferred income tax liability	342		-	-
13. Provisions for long-term payables	343		-	-
14. Science and technology development fund	344		-	-

ITEMS	Code	Notes	Ending balance	Beginning balance
D - OWNER'S EQUITY	400		604.740.334.821	454.420.627.481
1. Owner's capital	411	V.23	358.104.210.000	266.152.680.000
- *Ordinary shares with voting rights*	*411a*		*358.104.210.000*	*266.152.680.000*
- *Preferred shares*	*411b*		-	-
2. Share premiums	412	V.23	106.529.056.700	34.984.290.700
3. Bond conversion options	413		-	-
4. Other owner's capital	414		-	-
5. Share repurchases	415		-	-
6. Differences upon asset revaluation	416		-	-
7. Foreign exchange differences	417		-	-
8. Investment and development fund	418	V.23	114.368.190.306	101.242.219.168
9. Other equity funds	419		-	-
10. Retained profit/Accumulated loss	420	V.23	25.738.877.815	52.041.437.613
- *Retained profit/Accumulated loss to the end of the previous period*	*420a*		-	*52.041.437.613*
- *Retained profit/Accumulated loss for the current period*	*420b*		*25.738.877.815*	-
TOTAL LIABILITIES AND OWNER'S EQUITY	430		1.462.609.047.898	1.363.660.262.959

Approved, 12 August 2026

M.S.D.N: 160069... CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM T.P LONG XUYÊN

Do Thi Kim Len	Pham Do Phuong Thao	Nguyen Van Kha
Preparer	Acting Chief Accountant	Legal Representative

INTERIM INCOME STATEMENT

(Full form)

For the first 6 months of the fiscal year ending 31 December 2026

Unit: VND

ITEMS	Code	Notes	Accumulated from the beginning Current period	 Prior period
1. Revenue from sales of goods and provisions of services	**01**	**VI.1**	**454.079.483.173**	**409.783.064.337**
2. Revenue deductions	**02**	**VI.2**	**2.465.773.672**	**1.857.624.031**
3. Net revenue from sales of goods and provisions of services	**10**		**451.613.709.501**	**407.925.440.306**
4. Cost of sales	**11**	**VI.3**	**321.791.799.134**	**291.752.118.991**
5. Gross profit from sales of goods and provisions of services	**20**		**129.821.910.367**	**116.173.321.315**
6. Gain/loss on disposal, liquidation of investment properties	**21**		-	-
7. Financial income	**22**	**VI.4**	**725.970.171**	**274.353.608**
8. Financial expenses	**23**	**VI.5**	**23.501.596.273**	**20.856.576.319**
In which: Interest expenses	24		22.442.071.211	18.880.133.246
9. Selling expenses	**25**	**VI.6**	**51.200.867.087**	**46.914.133.258**
10. General and administrative expenses	**26**	**VI.7**	**23.855.687.797**	**21.478.189.285**
11. Net operating profit	**30**		**31.989.729.381**	**27.198.776.061**
12. Other income	**31**	**VI.8**	**220.821.182**	**3.158.686.633**
13. Other expenses	**32**		-	**115.000**
14. Other profit	**40**		**220.821.182**	**3.158.571.633**
15. Total accounting profit before tax	**50**		**32.210.550.563**	**30.357.347.694**
16. Current income tax	**51**	**V.17**	**6.471.672.748**	**5.906.875.969**
17. Deferred income tax	**52**		-	-
18. Profit after tax	**60**		**25.738.877.815**	**24.450.471.725**
19. Basic earnings per share	**70**	**VI.9a,b**	**737**	**758**
20. Diluted earnings per share	**71**	**VI.9a,b**	**737**	**758**

Approved, 12 August 2026

CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM

Do Thi Kim Len Preparer	Pham Do Phuong Thao Acting Chief Accountant	Nguyen Van Kha Legal Representative

This statement should be read in conjunction with the Notes to the Interim Financial Statements

INTERIM CASH FLOW STATEMENT

(Full form)
(Indirect method)
For the first 6 months of the fiscal year ending 31 December 2026

Unit: VND

	ITEMS	Code	Notes	Accumulated from the beginning of the year Current period	 Prior period
I.	**Cash flows from operating activities**				
1.	***Profit/loss before tax***	***01***		***32.210.550.563***	***30.357.347.694***
2.	***Adjustments for:***				
-	Depreciation/Amortization of fixed assets and investment properti	02	V.10, V.11, V.12	18.407.554.185	18.433.774.920
-	Provisions and allowances	03	V.6	395.354.064	277.861.521
-	Exchange gain/loss due to revaluation of monetary items in foreign currencies	04	VI.4, VI.5	(115.794.094)	330.989.924
-	Gain/loss from investing and financing activities	05	VI.4, VI,8	(484.013.700)	(2.873.454.392)
-	Borrowing costs	06	VI.5	22.442.071.211	18.880.133.246
-	Other adjustments	07		-	-
3.	***Operating profit/loss before movements in working capital***	***08***		***72.855.722.229***	***65.406.652.913***
-	Increase/decrease of receivables	09		(93.681.918.779)	3.545.851.030
-	Increase/decrease of inventories	10		(29.450.863.985)	(54.024.013.974)
-	Increase/decrease of payables	11		(58.498.546.773)	8.576.455.329
-	Increase/decrease of deferred expenses	12		143.339.993	(1.935.457.635)
-	Increase/decrease of trading securities	13		-	-
-	Interest expenses paid	14	V.18, VI.5	(22.304.049.967)	(18.914.083.482)
-	Corporate income tax paid	15	V.17	(14.202.643.939)	(11.722.011.234)
-	Other cash inflows	16		-	-
-	Other cash outflows	17	V.22, V.23	(12.392.326.398)	(7.043.893.569)
	Net cash flows generated from/(used in) operating activities	***20***		***(157.531.287.619)***	***(16.110.500.622)***
II.	**Cash flows from investing activities**				
1.	Purchases and construction of fixed assets and other non-current assets	21	V.4, V.10, V.11, V.13	(137.705.314.448)	(76.395.909.620)
2.	Proceeds from disposals of fixed assets and other non-current assets	22		22.969.663.881	9.010.746.737
3.	Cash outflow for lending, buying debt instruments of other entities	23		-	-
4.	Cash recovered from lending, selling debt instruments of other entities	24		98.404.390.567	-
5.	Equity investments in other entities	25		-	-
6.	Cash recovered from equity investments in other entities	26		-	-
7.	Interest earned, dividends and profits received	27	V.1, V.2b, VI.4	323.727.949	-
	Net cash flows generated from/(used in) investing activities	***30***		***(16.007.532.051)***	***(67.385.162.883)***

ITEMS	Code	Notes	Year-to-date Current period	Year-to-date Prior period
III. Cash flows from financing activities				
1. Proceeds from share issue and owners' contributed capital	31	V.23	126.771.436.000	20.829.546.000
2. Repayment for capital contributions and re-purchases of stocks already issued	32		-	-
3. Proceeds from borrowings	33	V.21a,b	375.477.589.971	388.120.415.179
4. Repayment for borrowing principal	34	V.21a	(343.959.232.840)	(285.313.193.660)
5. Payment for financial lease principal	35	V.21a,b	(14.278.934.087)	(10.607.151.926)
6. Dividends and profit paid to the owners	36		-	(11.343.723.000)
Net cash flows generated from/(used in) financing activities	***40***		***144.010.859.044***	***101.685.892.593***
Net cash flows during the period	**50**		**(29.527.960.626)**	**18.190.229.088**
Beginning cash and cash equivalents	**60**	**V.1**	**73.077.662.081**	**13.948.008.363**
Effects of fluctuations in foreign exchange rates	61		(10.057.841)	9.551.829
Ending cash and cash equivalents	**70**	**V.1**	**43.539.643.614**	**32.147.789.280**

Approved, 12 August 2026

CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM

Do Thi Kim Len	**Pham Do Phuong Thao**	**Nguyen Van Kha**
Preparer	**Acting Chief Accountant**	**Legal Representative**

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2026

I. GENERAL INFORMATION

1. Ownership form

Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as the "Company") is a joint stock company.

2. Business field

The Company operates in the industrial production and commercial trading sectors.

3. Principal business activities

Principal business activities of the Company are to manufacture medicines, pharmaceutical chemicals and pharmaceutical materials; trade optical, medical, dental and hospital equipment; trade medicines and pharmaceutical products; trade nutritious food; manufacture and trade cosmetics; trade materials and ancillary materials, pharmaceutical chemicals for pharmaceutical production; trade vaccines and medical biological products; manufacture bottled and jarred drinking water (the Company must comply with the Law on food safety and hygiene during operation course); manufacture dietary supplements; manufacture, trade and process essential oil from herbs; manufacture and trade food, nutritious food and dietary supplements.

4. Normal operating cycle

The Company's normal operating cycle is within 12 months.

5. Company structure

Joint ventures

The Company invests solely in USA-AGP Pharma, LLC, which has its registered office at 14314 Brookhurst Road, Garden Grove, California, 92843. The principal business activities of this joint venture are the packaging and sale of capsules and tablets in bottles, including functional foods, medicinal herbs, reishi mushrooms and cordyceps. At the end of the accounting period, the Company's ownership interest in this joint venture stood at 43,24% as the capital contribution had not yet been fully paid up; however, in accordance with Contractual arrangement No. 01/HDHTKD dated 18 March 2019, the Company's voting rights and percentage of ownership remain at 50 per cent.

Affiliates which are not legal entities

Affiliate	Address
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 49-51-53, Street No. 3A, An Lac Ward, Ho Chi Minh City
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 42 Nguyen Sinh Sac Street, Hoa Khanh Ward, Da Nang City
Branch of Agimexpharm Pharmaceutical Joint Stock Company - Agimexpharm Pharmaceutical Manufacturing Factory	No. 66 Vu Trong Phung Street, Thanh An Cluster, My Thoi Ward, An Giang Province
Branch of Agimexpharm Pharmaceutical Joint Stock Company – Binh Hoa Factory	Lot C4, Binh Hoa Industrial Park, Binh Hoa Commune, An Giang Province

Affiliate	Address
Agimexpharm Pharmaceutical Joint Stock Company – Tay Nguyen Branch	No. 184/84 Giai Phong Street, Buon Ma Thuot Ward, Dak Lak Province
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 46, Lane 105, Lang Ha Street, Dong Da Ward, Hanoi City

6. Headcount

As of the reporting date, the Company's headcount is 500 (headcount at the beginning of the year: 489).

7. Statement of information comparability on the Interim Financial Statements

The corresponding figures of the previous period are comparable with the figures of the current period. During the period, the Company applied for the first time to the Vietnamese Enterprise Accounting System issued under Circular No. 99/2025/TT-BTC dated 27 October 2025 of the Ministry of Finance ("Circular 99") in place of Circular No. 200/2014/TT-BTC dated 22 December 2014 ("Circular 200"). Accordingly, certain items in the Financial Statements have been reclassified and renamed in accordance with the new regulations. The figures in the "Beginning balance" and "Previous period" columns on the Interim Financial Statements have been restated in accordance with the new classifications and terminology set out in Circular 99 to ensure comparability. These changes do not affect the Company's total assets, total liabilities, owner's equity, and profit after tax.

8. Other information

The Company's shares have been listed on the Hanoi Stock Exchange under the stock code "AGP" pursuant to Decision No. 594/QĐ-SGDHN dated 11 September 2015 of the Hanoi Stock Exchange. The first trading day was 6 October 2015; the number of shares listed as at the end of the accounting period was 35.810.421 shares, with a par value of 10.000 VND per share.

II. ACCOUNTING PERIOD AND ACCOUNTING CURRENCY UNIT

1. Accounting period

The accounting period of the Company is from 01 January to 31 December annually.

2. Accounting currency unit

The accounting currency unit is Vietnamese Dong (VND) because transactions of the Company are primarily made in VND.

III. APPLICABLE ACCOUNTING STANDARDS AND SYSTEM

1. Applicable Accounting System

The Company applies the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, which were issued together with the Circular No. 99/2025/TT-BTC dated 27 October 2025 ("Circular 99") and the Circulars guiding the implementation of the Vietnamese Accounting Standards of the Ministry of Finance in the preparation and presentation of the Interim Financial Statements.

2. Statement of the compliance with the Accounting Standards and System

The Company's Board of Management has complied with all the requirements of the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, which were issued together with the Circular No. 99 as well as other Circulars guiding the implementation of Vietnamese Accounting Standards of the Ministry of Finance in the preparation and presentation of the Interim Financial Statements.

IV. APPLICABLE ACCOUNTING POLICIES, ACCOUNTING ESTIMATES AND RELEVANT LEGAL REQUIREMENTS

1. Accounting convention

The Financial Statements are prepared on the accrual basis (except for the information related to cash flows) using the historical cost principle and the going-concern assumption.

2. Foreign currency transactions

Transactions denominated in foreign currencies are translated at the spot exchange rate at the date of transaction. The balances of monetary items denominated in foreign currencies at the reporting date (excluding receivables denominated in foreign currencies for which allowances for doubtful debts have been made) are revalued at the average buying and selling rates applicable to wire transfer of Vietnam Joint Stock Commercial Bank of Industry and Trade – An Giang Branch (the Bank with which the Company regularly conducts transactions).

Exchange differences arising from the transactions denominated in foreign currency during the period, are recognized in financial income (if a gain) or financial expenses (if a loss). Exchange differences arising from the revaluation of foreign currency-denominated monetary items at the reporting date are presented on the basis of net amount of total gains and total losses arising from the revaluation of such items and are recognized in financial income (if a gain) or financial expenses (if a loss).

3. Cash and cash equivalents

Cash includes cash on hand and cash in bank. Cash equivalents are short-term investments with a maturity of three months or less from the date of investment (calculated from the date of purchase to the maturity date), which can be readily converted into a known amount of cash and are not subject to significant risks in conversion to cash at the reporting date. Restricted cash and cash equivalents are not presented under this item, but under the items "Other current assets" or "Other non-current assets", depending on the duration of the restriction.

4. Financial investments

Trading securities

Investments classified as trading securities are those held by the Company for the trading purpose with the aim of making profit from price differences.

Trading securities receive initial recognition at the fair value of the payments made at the time the transaction occurs. Costs associated with the purchase of trading securities (if any), such as brokerage fees, transaction costs, information fees, taxes and bank charges, are recognised as financial expenses for the period. During the holding period, the Company does not reclassify trading securities as held-to-maturity investments, nor vice versa.

The recognition date for trading securities is the date the Company obtains ownership rights, specifically as follows:

- For listed securities: recognized at the time of order-matching (T+0).
- For unlisted securities: recognized at the time of legally obtaining ownership in accordance with applicable laws and regulations.

Interest and dividends incurred prior to the acquisition of trading securities are deducted from the cost of such securities. Interest and dividends incurred after the acquisition of such securities are recorded in the Company's financial income. Dividends received in the form of shares are tracked solely by the increase in the number of shares held; the value of the shares received is not recognised.

Provisions for devaluation of trading securities are established for each type of securities traded on the market and whose fair value is lower than its cost. The fair value of trading securities is measured as follows:

- For listed securities or whose fair value can be reliably determined: the market value of the securities at the end of the accounting period.
- For trading securities for which fair value cannot be reliably determined at the end of the accounting period, the provision is recognised based on the loss incurred by the investee.
- For shares registered for trading on the trading market of unlisted public companies: the average reference price over the 30 consecutive trading days immediately preceding the end of the accounting period, as published by the Stock Exchange.
- In cases where shares listed on a stock exchange or shares of a joint-stock company registered for trading on the Upcom market have not been traded within the 30 days prior to the date of provisioning, or where listed shares have been delisted, suspended from trading or halted from trading: the provision is established based on the loss of the investee, with the provision amount calculated as the Company's percentage of actual paid-up share capital in the investee at the end of the accounting period multiplied (x) by the difference between the actual investment by the owners and the investee's owner's equity at the same time.

Increases/(decreases) in the provisions for impairment of trading securities that must be recognized at the balance sheet date are recorded into financial expenses.

Gain or loss from transfer of trading securities is recognized into financial income or financial expenses. The cost of trading securities is determined using the weighted average method. A change in the method used to determine the cost of trading securities shall be treated as a change in accounting policies.

Held-to-maturity investments

An investment is classified as a held-to-maturity investment when the Company has the intention and ability to hold it to maturity. The Company's held-to-maturity investments include: time deposits for the purpose of collecting periodic interest and other held-to-maturity investments or investments of a similar nature, and do not include derivative instruments.

Held-to-maturity investments are initially recognized at cost including the acquisition cost and other transaction costs. Interest incurred prior to the Company's acquisition of held-to-maturity investments is deducted from the costs at the acquisition time. Following initial recognition, these investments are carried at cost. Interest income after acquisition date is recognized in the Income Statement on an accrual basis.

Where a discount or premium arises at the time of purchase, the discount is amortized over the remaining term of the investment using the effective interest rate method, increasing the carrying amount of the investment and recognized as financial income; the premium is amortized using a similar method, reducing the carrying amount of the investment and recognized as financial expenses.

Where held-to-maturity investments with a floating interest rate are revalued periodically in line with market conditions, and where the update to the floating interest rate would offset the discount or premium relating to the instrument's advantage or disadvantage, the discount or premium is allocated over the period from the date of purchase to the next interest rate reset date (the date on which the bond's nominal interest rate is determined in accordance with market interest rate movements). Where a held-to-maturity investment has a floating interest rate that is reset periodically in line with market conditions, and the discount or premium relating to the instrument's advantages or disadvantages is not eliminated by the floating interest rate updates, the discount or premium is amortised over the life of the instrument.

When there is reliable evidence proving that a part or the whole investment cannot be recovered and the loss is reliably measured, the loss is recognized as financial expenses during the period and directly deducted from the investment costs. If the evidence of loss diminishes or ceases to exist in a subsequent period, the previously recognized loss is reversed and recognized as financial income for that period.

Investments in Joint ventures

Joint ventures

A joint venture is an entity which is established by a contractual arrangement whereby the Company and the involved parties undertake an economic activity that is subject to joint control. Joint control is understood as the requirement for strategic decisions regarding the operating and financial policies of the joint venture to be made with the consent of all parties involved in the joint venture.

Initial recognition

Investments in joint ventures are initially recognized at costs, including the cost of acquisition or capital contributions plus costs directly attributable to the investments (transaction costs, brokerage fees, consultancy fees, audit fees, duties, taxes, and bank charges, etc.). In the specific case where the Company borrows funds to invest in a Joint venture, interest expenses are recognised as financial expenses and are not capitalised. In cases where the investment is made through non-monetary assets, the cost of the investment is recognized at the fair value of the non-monetary assets at the time of occurrence. Following initial recognition, these investments are carried at cost.

Dividends and profits incurred prior to the acquisition of investments are deducted from investment costs. Dividends and profits for periods after the acquisition of the investment are recognised as financial income. Dividends received in the form of shares are accounted for by tracking only the increase in the number of shares held, with no recognition of the value of the shares received.

Provisions for impairment of investments in joint ventures

Provisions for impairment of investments in joint ventures are recognised when a joint venture incurs a loss or the investment suffers an impairment, resulting in the Company being likely to incur a loss of capital. The provision amount is determined by multiplying the Company's actual paid-in ownership interest (%) in the in the joint venture as at the end of the accounting period by the difference between the actual capital contributed by all owners and the associate's equity as at the same date. If the joint ventures are consolidated into the Consolidated Financial Statements, the basis for impairment provisions is the Consolidated Financial Statements.

Any increase or decrease in the provision for investment losses in joint ventures, which must be recognised at the end of the accounting period, is recorded as a financial expense.

5. Receivables

Receivables are recognized at their carrying amounts less allowances for doubtful debts.

The classification of receivables as trade receivables and other receivables is made according to the following principles:

- Trade receivables reflect receivables of a commercial nature arising from purchase and sale transactions between the Company and customers who are independent to the Company.
- Other receivables reflect receivables of a non-commercial nature that do not arise from purchase and sale transactions.

Receivables are tracked in detail by subject, term and original currency. The trade receivables and other receivables are classified as short-term and long-term items in the Statement of Financial Position on the basis of their remaining term as of the balance sheet date.

Allowance is made for each doubtful debt on the basis of estimated loss.

Increases and decreases in the balance of the allowance for doubtful debts at the end of the accounting period are recognised as general and administrative expenses.

6. Inventories

Inventories are stated at the lower of cost and net realizable value.

Cost of inventories is determined as follows:

- For materials and merchandise: Costs comprise costs of purchases and other directly attributable costs incurred in bringing the inventories to their present location and conditions.
- Work-in-process: comprises only the cost of primary materials and supplies.
- For finished goods: Costs comprise costs of materials, direct labor and directly relevant general manufacturing expenses allocated on the basis of normal operations.

Inventory costs are determined in accordance with the weighted average method and recorded in line with the perpetual method.

Net realizable value is the estimated selling price of inventories in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Allowance for devaluation of inventories is recognized for each type of inventories when their costs exceed their net realizable values. Increases or decreases in the obligatory allowance for devaluation of inventories as of the balance sheet date are recorded into costs of sales.

Materials, equipment and spare parts with a holding period of more than 12 months or more than one normal operating cycle, and products in process with a production or turnover period exceeding one normal operating cycle, shall not be presented as inventories but shall be presented as non-current assets in the Statement of Financial Position.

7. Deferred expenses

Deferred expenses reflect actual expenses incurred (including prepaid and unpaid expenses) relevant to financial performance in several accounting periods. These deferred expenses are allocated into operation costs of the relevant accounting periods.

In the Statement of Financial Position, deferred expenses are classified as short-term (with the maximum allocation period of 12 months or within a normal operating cycle) and long-term (with the allocation period of more than 12 months or longer than a normal operating cycle). Long-term deferred expenses shall not be re-classified as short-term when preparing the Interim Financial Statements.

The Company allocates deferred expenses into operation costs for each period, using an appropriate allocation method and criteria on the basis of the nature and extent of each type of expenses. The timing and method of allocating deferred expenses are as follows:

Tools and supplies
The tools and supplies put into use or leased out in connection with business operations in multiple accounting periods are recognized as deferred expenses and are allocated into operation costs on a straight-line basis over their estimated useful lives (3 years for maximum).

Expenses of fixed asset repairs
For fixed assets that must undergo periodic repairs and maintenance in accordance with technical requirements, the expenses for periodic repairs and maintenance are recognized as deferred expenses and allocated into operation costs on a straight-line basis from the date on which the repair and maintenance are completed and the assets are available for use until the next scheduled repair or maintenance (normally every 3 years).

Other deferred expenses
Other expenses incurred that relate to multiple accounting periods are recognised as deferred expenses and allocated to expenses.

8. Tangible fixed assets

Tangible fixed assets are presented at historical cost less any accumulated depreciation. Historical cost of tangible fixed assets comprises all costs incurred by the Company to acquire the assets up to the time when it is brought to its working condition for its intended use.

Subsequent costs are added to historical cost of fixed assets only if it is probable that future economic benefits associated with the asset will flow to the Company. Subsequent costs that do not meet the above conditions will be recognized as operation costs during the year. Costs of routine repairs and maintenance of tangible fixed assets are recognized into operation costs in the period in which they are incurred. For fixed assets that must undergo periodic repairs and maintenance in accordance with technical requirements, significant expenses incurred for repairing and maintaining these fixed assets are recognized as deferred expenses and amortized gradually into operation costs until the next routine repair or maintenance period.

Upon disposal or liquidation of a tangible fixed asset, its historical cost and accumulated depreciation are derecognised, then any gain or loss resulting from such disposal is included in the income or the expenses during the period.

Tangible fixed assets are depreciated in accordance with the straight-line method over their estimated useful lives. The useful life and amortization method are reviewed at least at the end of every fiscal year and adjusted if necessary. The depreciation periods for the various types of tangible fixed assets are as follows:

Fixed assets	Years
Buildings and structures	05 – 25
Machinery and equipment	02 – 15
Vehicles	05 – 10
Management equipment and tools	03 – 10

9. Financial leased assets

A lease is classified as a finance lease if it transfers substantially all the risks and rewards incident to ownership belonging to the lessee. Finance leased assets are presented at cost less accumulated depreciation. The historical cost of a finance lease asset is the lower of the fair value of the leased asset at the commencement of the lease term and the present value of the minimum lease payments.

The discount rate used to calculate the present value of the minimum lease payments is the implicit interest rate in the lease agreement. Where the implicit interest rate cannot be determined, the interest rate used is either the rate specified in the lease agreement or the Company's marginal borrowing rate at the commencement of the lease.

Financial leased assets are depreciated in accordance with the straight-line method over their estimated useful lives. If there is no reasonable certainty that the Company will obtain ownership at the end of the lease, the fixed asset shall be depreciated over the shorter of the lease term and the estimated useful life of the asset. The useful life and amortization method are reviewed at least at the end of every fiscal year and adjusted if necessary. The depreciation periods for the various types of financial leased assets are as follows:

Fixed assets	Years
Machinery and equipment	03 – 15

10. Intangible fixed assets

Intangible fixed assets are presented at their initial cost minus any accumulated amortization. Initial cost of intangible fixed assets includes all costs incurred by the Company to acquire the asset up to the time when it is brought to its working condition for its intended use. Subsequent costs attributable to intangible fixed assets are recognized as operation costs during the period in which they are incurred, unless such costs are directly attributable to a specific intangible fixed asset and increase the future economic benefits expected to be derived from that asset.

Upon disposal or liquidation of an intangible fixed asset, its initial cost and accumulated amortization are derecognised, then any gain or loss resulting from such disposal is included in the income or the expenses during the period.

The useful life and amortization method are reviewed at least at the end of every fiscal year and adjusted if necessary.

The Company's intangible fixed assets include:

Land use rights

Land use right comprises all the actual costs incurred by the Company that are directly attributable to the land in use, including payments made to obtain the land use right, compensation and site clearance costs, land levelling costs, registration fees and other directly attributable costs. Land use rights are amortized on a straight-line basis over 49 years. Long-term land use rights are not subject to amortization.

Computer software

Costs directly attributable to computer software that is not an integral part of the related hardware are capitalized. The cost of computer software includes all directly attributable costs incurred by the Company up to the date the software is available to use. Computer software programs are amortized on a straight-line basis over 5 years.

11. Construction in progress

Construction in progress reflect costs directly attributable to assets under construction and machinery and equipment being installed, including capitalised borrowing costs in accordance with Vietnamese Accounting Standard No. 16 – Borrowing Costs ("VAS 16"). These assets are recorded at historical cost and are not depreciated until they are available for use. Upon completion, all costs are transferred to the appropriate asset categories based on their intended use, including tangible fixed assets, intangible fixed assets, investment property or inventories, and depreciation/amortization commences when the assets are available for use.

Costs of upgrades and renovations of fixed assets in progress are accounted for separately and, upon completion, are added to the historical cost of the corresponding fixed assets.

Repair and maintenance expenses for fixed assets incurred on a regular basis to maintain the assets in their normal operating condition are recognized in operating expenses during the period. For fixed assets that must undergo periodic repairs and maintenance in accordance with technical requirements, the related costs are accumulated separately. Upon completion, the expenses are recognized as deferred expenses and amortized to operating expenses over the period until the next scheduled repair or maintenance.

12. Payables and accrued expenses

Payables and accrued expenses are recognized for amounts to be paid in the future in respect of merchandise and services received. Accrued expenses are recognized based on reasonable estimates of the amounts payable.

Payables are classified as trade payables, accrued expenses and other payables based on the following principles:

- Trade payables represent liabilities of a commercial nature arising from the purchase of goods, services or assets, where the suppliers are independent third parties of the Company.
- Accrued expenses represent liabilities for goods and services received from suppliers or provided to customers for which payment has not yet been made due to the absence of invoices or insufficient supporting documentation, as well as employee entitlements such as accrued annual leave and other operating expenses incurred but not yet settled (such as costs during seasonal production stoppages and interest expenses).
- Other payables represent liabilities of a non-commercial nature that do not arise from the purchase or sales of merchandise or provisions of services.

Payables and accrued expenses are classified as current or non-current on the Interim Statement of Financial Position based on their remaining maturity as of the end of the accounting period.

13. Payables for dividends and profit distributions

Dividends are recognized as liabilities when the Company has no right to refuse its obligation to pay dividends to shareholders under the provisions of securities law and the Company's Articles of Association.

Preference dividends are treated in accordance with the classification of preferred shares: where preferred shares are classified as liabilities, the corresponding dividend is not recognised from retained profit/accumulated loss. Where they are classified as Owner's equity, preferential dividends are treated in the same way as ordinary share dividends. Upon recognition of the payment obligation, dividends/profits payable in cash are recorded under 'Payables for dividends and profit distributions' and presented as a liability on the Statement of Financial Position.

14. Owner's equity

Owner's capital

The contributed capital is recorded according to the actual amounts invested by the shareholders.

Share premiums

Share premiums are recognised and comprise:

- The difference between the issue price and the nominal value of shares upon initial issue or additional issue.
- The difference between the value of capital contributions actually received and the value of capital as set out in the Company's Articles of Association.

Direct costs relating to the successful issue of shares are charged against share premiums. Costs arising from unsuccessful share issues are recognised as financial expenses for the period.

15. Profit distribution

Profit after tax is distributed to the shareholders after appropriation for funds under the Charter of the Company as well as legal regulations and approved by the General Meeting of Shareholders..

The distribution of profits to the shareholders is made with consideration toward non-cash items in the retained profit that may affect cash flows and payment of dividends such as profit due to revaluation of assets contributed as investment capital, profit due to revaluation of monetary items, financial instruments and other non-cash items.

16. Recognition of revenue and income

Revenue from sales of merchandise and finished goods

Revenue from sales of merchandise, finished goods shall be recognized when the Company fulfils its contractual obligations upon the transfer of control of goods and finished products to customers and all of the following conditions are satisfied:

- The Company transfers most of the risks and benefits incident to the ownership of merchandise or products to customers.
- The Company no longer retains the continuing managerial involvement to the degree usually associated with ownership nor effective control over the merchandise, products.
- The amount of revenue can be measured reliably.
- The Company received or shall probably receive the economic benefits associated with sale transactions.
- The costs incurred in respect of the sale transaction can be measured reliably.

Interest

Interest is recognized on a time-proportion basis using the effective interest rate for each period.

Dividends and profit received

For investments in entities whose securities are registered and centrally deposited with Viet Nam Securities Depository and Clearing Corporation, the recognition date is the last record date. For investments in other entities, the recognition date is decided in accordance with the Law on Enterprises and the Charter of the investee. The dividends received in the form of shares are not recognized in financial income and are accounted for by tracking only the increase in the number of shares held, with no recognition of the value of the shares received.

17. Revenue deductions

Revenue deductions include trade discounts, sales allowances and sales returns. These items are tracked separately and included into revenue from sales of goods and provisions of services to determine net revenue for the reporting period.

In case of products or merchandise provided in the previous years but trade discounts, sales allowances, sales returns incurred in the current year, the Company records a reduction in revenue in accordance with the following principles:

- If the revenue deductions arise prior to the publication of the Interim Financial Statements: this constitutes a post-balance-sheet event requiring adjustment and is recognized as a revenue deduction in the Interim Financial Statements for the reporting period
- If the revenue deductions arise after the publication of the Interim Financial Statements: they are recognized as revenue deductions for the period in which they arise.

18. Borrowing costs

Borrowing costs are interest and other costs that the Company incurs in connection with the borrowing.

Borrowing costs are recognized as an expense during the period when they are incurred, unless they are qualified for capitalized borrowing costs.

Borrowing costs that are directly attributable to the construction or the production of an asset in progress, which takes a substantial period of time (over 12 months) to get ready for intended use or sales, are capitalized as part of that asset when it is probable that they will result in future economic benefits to the Company and the borrowing costs can be reliably measured.

The capitalization of borrowing costs commences when all three of the following conditions are concurrently met:

- Expenditure for the construction or production of the asset have been incurred;
- Borrowing costs have been incurred; and
- Activities necessary to prepare the asset for its intended use or sale are being undertaken.

Capitalization is suspended during periods when the construction or production process is abnormally interrupted. Capitalization stops when substantially all activities necessary to prepare the asset for its intended use or sale have been completed.

For a specific borrowing for purpose of construction or production of an asset in progress, the capitalized borrowing costs are the actual borrowing costs incurred, less any investment income on the temporary investment of those borrowings.

In the event that general borrowings are partly used for the construction or production of an asset in progress, the costs eligible for capitalization will be determined by applying the capitalization rate to average accumulated expenditure on construction or production of that asset. The capitalization rate is computed at the weighted average interest rate of the borrowings outstanding during the period, except for borrowings made specifically for the purpose of obtaining an asset.

19. Expenses

Expenses are those that result in outflows of the economic benefits and are recorded at the time of transactions or when incurrence of the transaction is reliable regardless of whether payment for expenses is made or not. Expenses are recognized even if they are not yet due for payment, provided that their incurrence is reliable in order to ensure the principle of prudence and capital preservation.

When the Company recognizes revenue, it shall recognize the cost corresponding to generating that revenue. Such cost included those incurred in the period in which the revenue was generated together with cost incurred in the previous periods or accrued expenses related to the revenue generated in that period. In the event that matching principle conflicts with prudence principle, expenses are recognized based on the nature of the transaction and Vietnamese Accounting Standards in order to guarantee that transactions can be fairly and truly reflected.

20. Corporate income tax

The Company's corporate income tax accounting policy is implemented in accordance with the provisions of the Corporate Income Tax Law No. 67/2025/QH15 dated 14 June 2025, Decree No. 320/2025/NĐ-CP dated 15 December 2025 of the Government detailing certain provisions of the Corporate Income Tax Law, guidance documents issued by the Ministry of Finance, and other relevant legal provisions. Corporate income tax includes current income tax and deferred income tax.

Current corporate income tax

Current income tax includes the tax amount computed based on the assessable income during the period and the current corporate income tax rate. The assessable income is different from accounting profit due to the adjustments of temporary differences between tax and accounting figures, non-deductible expenses as well as those of non-taxable income and losses brought forward.

On a quarterly basis, the Company determines and recognizes the provisional corporate income tax payable based on the tax return. At the end of the fiscal year, the Company determines the actual corporate income tax payable based on the final tax return and adjusts any differences with the provisional amounts recognized during the year.

Deferred income tax

Deferred income tax is the amount of corporate income tax payable or refundable due to temporary differences between book values of assets and liabilities serving the preparation of the Financial Statements and the values for tax purposes.

Deferred income tax liabilities are recognized for all the temporary taxable differences, except to the extent that they arise from the initial recognition of an asset or liability in a transaction that, at the time of transaction, affects neither accounting profit nor taxable income.

Deferred income tax assets are recognized for all deductible temporary differences to the extent that future taxable income will be available against which the deductible temporary difference can be utilized. Deferred income tax assets are also recognized for unused taxable losses and tax credits to the extent that it is probable that future taxable profit will be available against which they can be utilized. Deferred income tax assets and deferred income tax liabilities arising from transactions recognized directly in owner's equity are not recognized into deferred income tax expense.

The carrying amount of deferred corporate income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be recovered.

Deferred income tax assets and deferred income tax liabilities are measured using the tax rates that are expected to apply in the period when the assets are recovered or the liabilities are settled, based on the effective tax rates and tax laws that have been enacted or substantively enacted by the reporting date.

When preparing the Statement of Financial Position, the Company offsets deferred tax assets and deferred tax liabilities if:

- The Company has the legal right to offset current income tax assets against current income tax liabilities; and
- Deferred income tax assets and deferred income tax liabilities are relevant to corporate income tax levied by the same taxation authority on either:
  - The same taxable subjects; or
  - The Company has intention to pay current income tax liabilities and current income tax assets on a net basis or recover tax assets and settle tax liability simultaneously in each future period in which significant amounts of deferred tax liabilities or deferred tax assets are expected to be settled or recovered.

21. Related party

A party is considered a related party of the Company if that party has the ability to control the Company or exercise significant influence over the Company, or has power to participate in financial and operating policy decisions of the Company. A party is also considered a related party of the Company if both parties are subject to common control.

Related parties of the Company include:

- Joint ventures within the same group.
- Individuals with direct or indirect voting rights and thereby have significant influence over the Company, including members of the Board of Directors and their close family members.
- Key management personnel with the authority and responsibility to plan, manage and control the Company's operations, including the members of the Board of Management, other management members and their close family members.
- Entities over which individuals referred to above are able to exercise sufficient influence through direct or indirect ownership of voting rights, including entities owned by key management personnel or major shareholders of the Company and entities that share key management personnel with the Company.

Close family members of an individual are those who may cause influence or be influenced by that individual in their dealings with the Company, including the individual's parents, spouse, children and siblings.

A related party transaction is a transfer of resources, services or obligations between related parties, regardless of whether a price is charged.

In considering if parties are related, attention is directed to the substance of the relationship and not merely its legal form.

22. Segment reporting

A business segment is a distinguishable component of the Company that is engaged in manufacturing or providing products or services and that is subject to risks and returns that are different from those of other business segments.

A geographical segment is a distinguishable component of the Company that is engaged in manufacturing or providing products or services within a particular economic environment and that is subject to risks and returns that are different from those of components operating in other economic environments.

The nature of economic risks and benefits is the primary basis for determining whether the primary segment report is prepared by the business field or geographical area. If risks and rates of return are primarily influenced by differences in products and services, the primary segment report is prepared by the business field and the secondary segment report is prepared by geographical area. Conversely, if risks and rates of return are primarily influenced by differences in geographical area, the primary segment report is prepared by geographical area and the secondary segment report is prepared by the business field. The Company's organizational structure, management and internal financial reporting system form the primary basis for determining whether a segment report is primary or secondary.

A segment must be reported if the majority of its revenue derives from external sales of goods and provisions of services and meets at least one of the following thresholds:

- The segment's revenue accounts for 10% or more of the total revenue of all segments.
- The segment's financial performance accounts for 10% or more of the total financial performance of all profitable segments or the total financial performance of all loss-making segments (whichever is greater in absolute terms).
- The segment's total assets account for 10% or more of the total assets of all segments.

The segment information is prepared and presented in conformity with the accounting policies applicable to the preparation and presentation of the Interim Financial Statements of the Company.

V. SUPPLEMENTARY INFORMATION FOR ITEMS PRESENTED IN THE INTERIM FINANCIAL STATEMENTS

1. Cash and cash equivalents

	Ending balance	Beginning balance
Cash on hand	7.815.584.089	7.860.159.984
Cash in bank	29.714.689.662	19.229.091.471
- Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch	*5.923.258.312*	*3.508.092.484*
- Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – Da Nang Branch	*6.601.748.466*	*5.261.061.616*
- Joint Stock Commercial Bank for Foreign Trade of Vietnam (Vietcombank) – An Giang Branch	*10.001.474.070*	*5.219.358.701*

	Ending balance	Beginning balance
- Other banks	*7.188.208.814*	*5.240.578.670*
Cash equivalents	6.009.369.863	45.988.410.626
- 1-month term deposit with Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch	-	*45.985.764.870*
- 1-month term deposit at Shinhan Bank Vietnam Limited – North Saigon Branch	*6.000.000.000*	-
- Accrued interest	*9.369.863*	*2.645.756*
Total	**43.539.643.614**	**73.077.662.081**

2. Financial investments

The financial investments of the Company include trading securities, held-to-maturity investments, and equity investments in other entities. The Company's financial investments are as follows:

2a. Trading securities

	Ending balance			Beginning balance		
	Original amount	Fair values	Provisions	Original amount	Fair values	Provisions
Shares						
Imexpharm Corporation	1.052.350.306	6.515.203.200	-	1.052.350.306	8.302.140.000	-
Mekophar Chemical Pharmaceutical Joint-Stock Company	45.300.950	137.721.000	-	45.300.950	119.199.900	-
Total	**1.097.651.256**	**6.652.924.200**	-	**1.097.651.256**	**8.421.339.900**	-

2b. Held-to-maturity investments

	Ending balance			Beginning balance		
	Original amount	Recoverable amount	Provisions	Original amount	Recoverable amount	Provisions
Short-term						
Fixed-term deposits	5.000.000.000	5.000.000.000	-	5.000.000.000	5.000.000.000	-
- Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch	*5.000.000.000*	*5.000.000.000*	-	*5.000.000.000*	*5.000.000.000*	-
Expected term deposit interest	191.589.041	191.589.041	-	88.027.397	88.027.397	-
Total	**5.191.589.041**	**5.191.589.041**	-	**5.088.027.397**	**5.088.027.397**	-

This deposit has been mortgaged to secure borrowings from the Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch (see note V.21a).

2c. *Equity investments in other entities*

	Ending balance			Beginning balance		
	Original amount	**Recoverable amount**	**Provisions**	**Original amount**	**Recoverable amount**	**Provisions**
Investment in joint ventures						
USA-AGP Pharma, LLC [(i)]	17.130.750.000			17.130.750.000		
Total	**17.130.750.000**			**17.130.750.000**		

(i) According to Investment Certificate No. 201900695, initially registered on 19 July 2019 and amended for the first time on 9 April 2022, issued by the Ministry of Planning and Investment, the Company has invested in USA-AGP Pharma, LLC VND 19.663.050.000 (equivalent to USD 850.000), equivalent to 50% of charter capital. As at the end of the accounting period, the Company invested VND 17.130.750.000 (USD 735.000), equivalent to 43,24% of charter capital. The charter capital to be invested in USA-AGP Pharma, LLC is VND 2.532.300.000 (equivalent to USD 115.000).

Recoverable amount

For investments in listed shares or investments for which a fair value can be reliably determined, the recoverable amount is determined based on the market value at the end of the accounting period.

For investments for which fair value cannot be determined, the recoverable amount is determined based on the investee's owner's equity, as a proportion of the Company's ownership interest, as shown in the Consolidated Financial Statements (if the investee is a parent company) or the separate financial statements (if the investee is an independent entity with no subsidiaries) as at the end of the accounting period.

The Company has not yet been able to determine the recoverable amount of its investment in USA-AGP Pharma, LLC as the investee has not provided reliable financial information. Consequently, the Company has no basis for recognising a provision for impairment on this investment. The Company will reassess the situation once sufficient information is available.

Operating performance of joint ventures

USA-AGP Pharma, LLC has completed the construction of its manufacturing plant in accordance with the objectives set out in the Overseas Investment Registration Certificate. USA-AGP Pharma, LLC has now finalised all necessary procedures and obtained the required licences, and has commenced production and business operations.

Transactions with joint ventures

Transactions between the Company and its Joint ventures are presented in Note No. VII.1b.

3. Short-term trade receivables

	Ending balance		Beginning balance	
	Carrying amount	Allowances	Carrying amount	Allowances
Receivables from related parties	***3.367.107.470***	-	***904.459.010***	-
Imexpharm Corporation	2.462.648.460	-	-	-
USA-AGP Pharma, LLC	904.459.010	-	904.459.010	
Receivables from other customers	***180.951.768.444***	***4.996.072.937***	***153.424.157.765***	***4.600.718.873***
Pharmacity Pharmacy Joint Stock Company	15.046.355.889	-	12.909.406.111	-
Other customers	165.905.412.555	4.996.072.937	140.514.751.654	4.600.718.873
Total	**184.318.875.914**	**4.996.072.937**	**154.328.616.775**	**4.600.718.873**

Certain trade receivables with a carrying amount of VND 107.000.000.000 as at the end of the accounting period have been pledged as collateral for bank borrowings (see Note V.21a).

4. Short-term advances to suppliers

	Ending balance	Beginning balance
Nguyen Phuc Mechanical Joint Stock Company	-	1.102.811.883
Central Institute for Pharmaceutical Control	900.000.000	1.507.920.000
Thanh Y Fabrication Machine Joint Stock Company	1.342.000.000	-
Kien An Construction Architecture Design Consultancy Company Limited	5.576.439.000	-
Other suppliers	3.940.384.428	3.362.814.142
Total	**11.758.823.428**	**5.973.546.025**

	Ending balance	Beginning balance
In which:		
Short-term advances to suppliers for the acquisition of fixed assets/construction in progress	7.349.985.000	2.101.594.011

5. Other receivables

5a. Other short-term receivables

	Ending balance		Beginning balance	
	Carrying amount	Allowances	Carrying amount	Allowances
Receivables from related party	***30.270.012.515***	-	***20.312.329.806***	-
Member of the Board of Management – Advance payment for sales system development	30.270.012.515	-	20.312.329.806	-
Other receivables from other organisations and individuals	***93.996.192.594***	-	***58.702.853.620***	-
Advances (i)	42.399.875.233	-	16.492.240.356	-
Short-term mortgages and deposits	24.986.294.263	-	25.203.978.542	-

	Ending balance		Beginning balance	
	Carrying amount	Allowances	Carrying amount	Allowances
Vietnam International Leasing Company Limited – Prepaid lease payments under finance lease contracts	14.772.960.000	-	14.772.960.000	-
Vietnam International Leasing Company Limited – Receivables from import consignment	7.971.882.400	-	-	-
Other short-term receivables	3.865.180.698	-	2.233.674.722	-
Total	**124.266.205.109**	-	**79.015.183.426**	-

(i) Advances for the development of the sales system and the Company's business operations.

5b. Other long-term receivables

	Ending balance		Beginning balance	
	Carrying amount	Allowances	Carrying amount	Allowances
Advances for expenses incurred in preparation for investment activities	10.750.000.000	-	-	-
Long-term mortgages and deposits	25.462.958.704	-	23.772.155.478	-
- Vietnam International Leasing Company Limited	*16.984.350.000*	-	*16.984.350.000*	-
- Chaileas International Leasing Company Limited	*5.637.186.969*	-	*5.873.186.969*	-
- Other long-term mortgages and deposits	*2.841.421.735*	-	*914.618.509*	-
Other long-term receivables	6.902.268.976	-	-	-
Total	**43.115.227.680**	-	**23.772.155.478**	-

6. Doubtful debts

	Ending balance		Beginning balance	
	Original amount	Recoverable amount	Original amount	Recoverable amount
Receivables from other organizations and individuals - *Trade receivables*	4.996.072.937	-	4.600.718.873	-
Total	**4.996.072.937**	-	**4.600.718.873**	-

Fluctuations in allowances for short-term doubtful debts are as follows:

	Accumulated from the beginning of the year	
	Current year	Previous year
Beginning balance	4.600.718.873	4.375.357.352
Additional extraction of allowance	395.354.064	277.861.521
Ending balance	**4.996.072.937**	**4.653.218.873**

7. Inventories

	Ending balance		Beginning balance	
	Cost	Allowances	Cost	Allowances
Materials and supplies	205.584.675.337	-	175.704.568.367	-
Work-in-process	23.582.929.579	-	19.440.823.444	-
Finished goods	140.101.705.554	-	144.671.276.715	-
Merchandise	1.583.144.100	-	1.509.185.272	-
Goods on consignment	49.396.016	-	125.132.803	-
Total	**370.901.850.586**	-	**341.450.986.601**	-

Some inventories with a carrying amount of VND 255.000.000.000 have been mortgaged as security for borrowings from banks (see note V.21a).

8. Deferred expenses

8a. Short-term deferred expenses

	Ending balance	Beginning balance
Tools and supplies	76.031.745	-
Property insurance premiums	270.785.525	627.212.436
Infrastructure usage costs	130.112.669	-
Other short-term prepaid expenses	75.000.000	76.205.382
Total	**551.929.939**	**703.417.818**

8b. Long-term deferred expenses

	Ending balance	Beginning balance
Tools and supplies	6.538.041.111	6.920.235.741
Expenses of fixed asset repairs	4.057.469.422	5.247.988.497
Biological equivalence testing costs	2.953.848.464	-
Other long-term prepaid expenses	4.346.705.269	5.707.392.140
Total	**17.896.064.266**	**17.875.616.378**

9. Other current assets

	Ending balance	Beginning balance
Blocked deposits	-	98.404.390.567
Total	-	**98.404.390.567**

10. Tangible fixed assets

Increases/(decreases) of tangible fixed assets are presented in the attached Appendix 01.

Some tangible fixed assets, of which the carrying value is VND 267.411.912.452, have been mortgaged to secure the borrowings from Banks (see notes V.21a and V.21b).

The list of tangible fixed assets at the end of the accounting period is as follows:

	Historical cost	Accumulated depreciation	Carrying value
Buildings and structures	***346.249.867.084***	**75.390.964.472**	***270.858.902.612***
Betalactam Plant – Binh Hoa	167.035.354.357	9.968.689.116	157.066.665.241
Non-Betalactam Plant – Binh Hoa	46.367.418.754	6.402.732.111	39.964.686.643

	Historical cost	Accumulated depreciation	Carrying value
Buildings and structures	132.847.093.973	59.019.543.245	73.827.550.728
Machinery and equipment	***142.471.194.234***	**103.488.595.531**	***38.982.598.703***
Other machinery and equipment	142.471.194.234	103.488.595.531	38.982.598.703
Vehicles	***15.197.618.771***	**11.411.410.866**	***3.786.207.905***
Other vehicles	15.197.618.771	11.411.410.866	3.786.207.905
Management equipment and tools	***4.269.788.450***	**2.042.934.254**	***2.226.854.196***
Other management equipment and tools	4.269.788.450	2.042.934.254	2.226.854.196
Total	**508.188.468.539**	**192.333.905.123**	**315.854.563.416**

Details of tangible fixed assets disposed of during the period are as follows:

	Historical cost	Accumulated depreciation	Carrying value	Disposal value
Machinery and equipment	***23.548.918.239***	***616.954.356***	***22.931.963.883***	***22.919.663.881***
Air-conditioning systems – Liquid-cooled plants	14.458.736.692	-	14.458.736.692	14.446.436.692
Boiler	2.550.000.000	-	2.550.000.000	2.550.000.000
CKD tablet press	2.457.034.534	273.003.836	2.184.030.698	2.184.030.698
Other machinery and equipment	4.083.147.013	343.950.520	3.739.196.493	3.739.196.491
Vehicles	***740.000.000***	***740.000.000***	-	***50.000.000***
8-seater Toyota, registration number 51A-584.65 (Sienna)	740.000.000	740.000.000	-	50.000.000
Total	**24.288.918.239**	**1.356.954.356**	**22.931.963.883**	**22.969.663.881**

11. Financial leased assets

	Machinery and equipment
Historical cost	
Beginning balance	68.420.125.038
Increases during the period	22.919.563.881
Ending balance	**91.339.688.919**
Depreciation	
Beginning balance	6.701.224.019
Depreciation for the period	5.277.360.297
Ending balance	**11.978.584.316**
Carrying value	
Beginning balance	61.718.901.019
Ending balance	**79.361.104.603**

The list of financial leased assets at the end of the accounting period is as follows:

	Historical cost	Accumulated depreciation	Carrying value
Air-conditioning system – Liquid-cooled plant	14.446.436.692	-	14.446.436.692
Other financial leased assets	76.893.252.227	11.978.584.316	64.914.667.911
Total	**91.339.688.919**	**11.978.584.316**	**79.361.104.603**

12. Intangible fixed assets

	Land use rights (*)	Computer software	Total
Initial cost			
Beginning balance	18.706.085.532	1.804.078.844	20.510.164.376
Ending balance	**18.706.085.532**	**1.804.078.844**	**20.510.164.376**
In which:			
Assets fully amortized but still in use	-	1.804.078.844	1.804.078.844
Assets waiting for liquidation	-	-	-
Amortization			
Beginning balance	557.655.639	1.804.078.844	2.361.734.483
Depreciation for the period	18.588.522	-	18.588.522
Ending balance	**576.244.161**	**1.804.078.844**	**2.380.323.005**
Carrying value			
Beginning balance	18.148.429.893	-	18.148.429.893
Ending balance	**18.129.841.371**	-	**18.129.841.371**
In which:			
Assets temporarily not in use	-	-	-
Assets waiting for liquidation	-	-	-

(*) In which, the land use right of which carrying value of VND 18.129.841.371 has been mortgaged to secure the borrowings from Banks (see Note No. V.19a).

	Initial cost	Accumulated amortization	Carrying value
Land use rights	***18.706.085.532***	***576.244.161***	***18.129.841.371***
Land use rights for plots Nos. 70 and 80, map sheet No. 11, My Thoi Ward, An Giang Province, with a total area of 1.469,8 m²	3.587.954.000	-	3.587.954.000
Land use rights for plot No. 160, map sheet No. 11, My Thoi Ward, An Giang Province, with an area of 2.175,9 m²	3.198.573.000	-	3.198.573.000
Land use rights for plots Nos. 322-597, 322-598 and 322-599, Map Sheet No. 10 (TL02/CT-UB), Binh Tri Dong B Ward, Ho Chi Minh City, with an area of 300 m²	8.500.000.000	-	8.500.000.000
Other land use rights	3.419.558.532	576.244.161	2.843.314.371
Computer software	***1.804.078.844***	***1.804.078.844***	-
Total	**20.510.164.376**	**2.380.323.005**	**18.129.841.371**

13. Construction in progress

Information on movements in construction in progress costs is set out in the attached Appendix 02.

14. Short-term trade payables

	Ending balance	Beginning balance
Payables to related party	***3.852.697.837***	***3.031.598.285***
Imexpharm Corporation	3.852.697.837	3.031.598.285
Payables to other suppliers	***152.405.059.534***	***90.847.706.195***
Branch Glandcore Company Limited	26.416.604.692	15.843.717.996
Toan Phuc Pharmaceutical Chemical Company Limited	30.707.922.123	-
Khang Gia Construction and Architect Design Company Limited	-	10.367.407.336
Other suppliers	95.280.532.719	64.636.580.863
Total	**156.257.757.371**	**93.879.304.480**

	Ending balance	Beginning balance
In which:		
Short-term trade payables for acquisition of fixed assets/ construction in progress	660.404.652	15.783.370.430

The Company has no overdue trade payables.

15. Short-term advances from customers

	Ending balance	Beginning balance
Thien Dien Pharmaceutical Joint Stock Company	2.585.587.935	2.999.999.997
Global Pharmaceutical Joint Stock Company	-	1.908.674.679
Hien Mai Pharmaceutical Limited Company	1.261.000.000	461.000.000
Ms Le Bich Ngoc	719.550.021	717.987.229
Duke University	1.144.302.300	1.144.302.300
Other customers	2.000.076.542	2.228.115.426
Total	**7.710.516.798**	**9.460.079.631**

16. Payables for dividends and profit distributions

Dividends payable past their due date amount to VND 267.381.200 (beginning balance: VND 267.381.200). The delay in paying these dividends is due to the Company awaiting shareholders' bank account details.

17. Taxes and other obligations to the State Budget

Changes in taxes and other obligations to the State Budget are set out in the attached Appendix 03.

Value Added Tax

The Company pays value added tax using the deduction method. The tax rates applied are as follows:

- Group of medicinal products and pharmaceuticals of all kinds 5%
- Cosmetics and functional foods 10%

During the period, the Company is subject to a VAT rate of 8% on merchandise and services currently subject to a 10%, in accordance with the provisions of Clauses 1 and 2, Article 1, of Government Decree No. 174/2025/NĐ-CP dated 30 June 2025.

Corporate income tax

The Company has to pay corporate income tax at the rate of 20% on taxable income.

In 2020, the Company commissioned the Binh Hoa Herbal Medicine Plant Project in an area with difficult socio-economic conditions. In accordance with the provisions of the current Corporate Income Tax Law, the project is eligible for a tax incentive with a 17% corporate income tax rate for 10 years on income from business activities in this area, and is exempt from tax for two years, with a 50% reduction in the corporate income tax payable for the following four years. The year 2026 marks the seventh year in which the project is eligible for the tax incentive at a rate of 17% on income from business operations in this area.

The estimated corporate income tax payable for the period is as follows:

	Cumulative from the start of the year to the end of this period	
	Current year	**Previous year**
Total accounting profit before tax	32.210.550.563	30.357.347.694
Increases/(decreases) of accounting profit to determine taxable income:		
- Increases	645.401.838	504.694.855
- Decreases	(2.067.189)	(13.775.089)
Taxable income	32.853.885.212	30.848.267.460
Income exempted from tax	-	(2.374.500)
Assessable income	32.853.885.212	30.845.892.960
Corporate income tax rate	20%	20%
Corporate income tax payable at common tax rate	***6.570.777.042***	***6.169.178.592***
Differences due to the application of rate other than common tax rate	***(99.104.294)***	***(68.426.771)***
Corporate income tax reduced	***-***	***(193.875.852)***
Corporate income tax to be paid	**6.471.672.748**	**5.906.875.969**

Determination of corporate income **tax** liability of the Company is based on currently applicable regulations on tax. Nonetheless, these tax regulations may change from time to time and tax regulations applicable to variety of transactions can be interpreted differently. Hence, the tax amounts presented in the Financial Statements can be changed upon the inspection of tax authorities.

Land rental

The Company is required to pay land rental for the plots of land it is currently using at the following rates:

Land location	Rent rate
- No. 151, Dinh Tien Hoang Street, Long Xuyen Ward, An Giang Province, area 208 m^2	259.200 VND/m^2/year
- No. 27, Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, area2.636 m^2	1.036.800 VND/m^2/year

- No. 01, Phan Dinh Phung Street, Long Xuyen Ward, An Giang Province, area 57 m²	604.800 VND/m²/year
- My Thoi Ward, An Giang Province, area 3.023 m²	72.000 VND/m²/year
- My Thoi Ward, An Giang Province, area 132,7 m²	25.920 VND/m²/year

Property tax

Property tax is paid according to the notices of the tax department.

Other taxes, fees, legal fees, and other duties

The Company has declared and paid these amounts in line with the prevailing regulations.

18. Short-term accrued expenses

	Ending balance	Beginning balance
Interest expenses	845.299.074	707.277.830
Commissions and sales promotions	-	863.232.590
Total	**845.299.074**	**1.570.510.420**

19. Deferred revenue

This item reflects the gain on sales of financial leased assets.

20. Other short-term payables

	Ending balance	Beginning balance
Trade Union's expenditure	348.023.486	318.295.624
Payable from import consignment	7.971.882.400	43.585.842.100
Advances from subscribers for shares	-	98.372.000.000
Other short-term payables	97.943.390	204.160.668
Total	**8.417.849.276**	**142.480.298.392**

The Company has no other overdue payables.

21. Borrowings and financial lease liabilities

21a. Short-term borrowings and financial lease liabilities

	Ending balance	Beginning balance
Short-term borrowings from banks	434.458.716.694	481.084.422.453
- *Borrowings from Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch (i)*	*248.217.648.347*	*246.902.476.537*
- *Borrowing from Prosperity and Growth Commercial Joint Stock Bank – An Giang Branch (ii)*	*922.390.000*	*20.441.566.778*
- *Borrowing from Joint Stock Commercial Bank for Foreign Trade of Vietnam – An Giang Branch ((iii)*	*90.241.922.623*	*93.123.776.008*
- *Borrowing from Vietnam Technological and Commercial Joint Stock Bank (Techcombank) – Cho Lon Branch (iv)*	*19.499.858.733*	*82.602.553.565*
- *Borrowing from Shinhan Bank Vietnam Limited – North Saigon Branch (v)*	*29.990.232.510*	*29.996.691.421*

	Ending balance	Beginning balance
- *Borrowing from Hong Leong Bank Vietnam Limited* [(vi)]	*45.586.664.481*	*8.017.358.144*
Short-term borrowings from individuals [(vii)]	400.000.000	400.000.000
Current portions of long-term borrowings (see note V.21b)	14.400.000.000	14.400.000.000
Current portions of financial lease liabilities (see note V.21b)	24.018.837.022	19.709.999.896
Total	**473.277.553.716**	**515.594.422.349**

The Company is capable of repaying its short-term borrowings and financial lease liabilities.

(i) A borrowing from the Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch to supplement working capital for production and business operations; the borrowing term for each disbursement shall not exceed 12 months, with interest rates applicable to each disbursement. The borrowing is secured by the pledge of savings books and the mortgage of the Company's receivables, inventories, buildings and structures, machinery and equipment, vehicles, management equipment and tools, and land use rights (see notes V.2b, V.3, V.7, V.10 and V.12).

(ii) A borrowing from Prosperity and Growth Commercial Joint Stock Bank – An Giang Branch to supplement working capital for production and business operations; the term of each drawdown shall not exceed 12 months, with interest rates applicable to each drawdown. The borrowing is secured by a mortgage on the Company's land use rights (see note V.12).

(iii) A borrowing from the Joint Stock Commercial Bank for Foreign Trade of Vietnam (Vietcombank) – An Giang Branch to supplement working capital for production and business operations; the term of each drawdown shall not exceed 12 months, with interest rates applicable to each drawdown. The borrowing is secured by a mortgage over the Company's inventories, machinery and equipment, and land use rights (see notes V.7, V.10 and V.12).

(iv) A borrowing from Vietnam Technological and Commercial Joint Stock Bank (Techcombank) – Cho Lon Branch to supplement working capital for production and business operations; the term of each drawdown shall not exceed 12 months, with interest rates applicable to each drawdown. The borrowing is secured by a charge on the Company's receivables and Inventories, and by a pledge of third-party assets (see notes V.3, V.7 and VII.1a).

(v) A borrowing from Shinhan Bank Vietnam Limited – North Saigon Branch to supplement working capital for production and business operations; the term of each drawdown shall not exceed 12 months, with interest rates applicable to each drawdown. The borrowing is secured by a pledge of third-party assets (see Note VII.1a).

(vi) A borrowing from Hong Leong Bank Vietnam Limited to supplement working capital for production and business operations; the term of each drawdown shall not exceed 12 months, with the interest rate determined for each drawdown. The borrowing is secured by a pledge of third-party assets (see Note VII.1a).

(vii) Unsecured borrowings from external individuals and Company employees to supplement working capital for production and business operations, at an interest rate of 7,5%/year.

Details of increases/(decreases) of short-term borrowings and financial lease liabilities during the period are as follows:

	Beginning balance	Increase during the period	Transfer from long-term borrowings and non-current liabilities	Amount repaid during the period	Ending balance
Short-term borrowings from banks	481.084.422.453	290.133.527.081	-	(336.759.232.840)	434.458.716.694
Short-term borrowings from individuals	400.000.000	-	-	-	400.000.000
Current portions of long-term borrowings	14.400.000.000	-	7.200.000.000	(7.200.000.000)	14.400.000.000
Current portions of financial lease liabilities	19.709.999.896	-	15.471.251.480	(11.162.414.354)	24.018.837.022
Total	**515.594.422.349**	**290.133.527.081**	**22.671.251.480**	**(355.121.647.194)**	**473.277.553.716**

21b. Long-term borrowings and financial lease liabilities

	Ending balance	Beginning balance
Long-term bank borrowings	82.077.000.000	89.277.000.000
Borrowings from Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch (i)	*82.077.000.000*	*89.277.000.000*
Finance lease liabilities	117.031.290.663	27.355.435.105
Finance lease with Chaileas International Leasing Company Limited to support production and business operations, term of 36 months	*12.002.280.890*	*17.391.846.346*
Finance lease from Vietnam International Leasing Company Limited to support production and business operations, for a term of 36–60 months	*92.535.321.987*	*9.963.588.759*
Finance lease from Joint Stock Commercial Bank for Foreign Trade of Vietnam (Vietcombank) Financial Leasing Company Limited, Ho Chi Minh City Branch, to support production and business operations, for a term of 48 months	*12.493.687.786*	-
Total	**199.108.290.663**	**116.632.435.105**

The Company is capable of repaying its long-term borrowings and financial lease liabilities.

(i) A borrowing from the Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch to cover the investment costs of the Beta-lactam Antibiotic Production Plant project, with interest rates as specified in each promissory note and a borrowing term of nine years from the date of the first disbursement. The borrowing is repaid quarterly, with a 16-month grace period on the principal. This borrowing is secured by a mortgage on buildings and structures (see note V.10).

Repayment schedule of long-term borrowings and financial lease liabilities is as follows:

	Total debt	1 year or less	More than 1 year to 5 years	More than 5 years
Ending balance				
Long-term bank borrowings	96.477.000.000	14.400.000.000	57.600.000.000	24.477.000.000
Finance lease liabilities	141.050.127.685	24.018.837.022	117.031.290.663	-
Total	**237.527.127.685**	**38.418.837.022**	**174.631.290.663**	**24.477.000.000**
Beginning balance				
Long-term bank borrowings	103.677.000.000	14.400.000.000	57.600.000.000	31.677.000.000
Finance lease liabilities	47.065.435.001	19.709.999.896	27.355.435.105	-
Total	**150.742.435.001**	**34.109.999.896**	**84.955.435.105**	**31.677.000.000**

Total financial lease liabilities are as follows:

	1 year or less	More than 1 year to 5 years	Total
Ending balance			
Principal repayable	24.018.837.022	117.031.290.663	141.050.127.685
Lease interest payable	3.741.776.274	2.641.305.073	6.383.081.347
Financial lease liabilities	**27.760.613.296**	**119.672.595.736**	**147.433.209.032**
Beginning balance			
Principal repayable	19.709.999.896	27.355.435.105	47.065.435.001
Lease interest payable	2.853.592.223	1.966.340.083	4.819.932.306
Financial lease liabilities	**22.563.592.119**	**29.321.775.188**	**51.885.367.307**

Details of increases/(decreases) of long-term borrowings and financial lease liabilities are as follows:

	Beginning balance	Increase during the period	Amount repaid during the period	Transferred to short-term borrowings	Ending balance
Long-term bank borrowings	89.277.000.000	-	-	(7.200.000.000)	82.077.000.000
Finance lease liabilities	27.355.435.105	108.263.626.771	(3.116.519.733)	(15.471.251.480)	117.031.290.663
Total	**116.632.435.105**	**108.263.626.771**	**(3.116.519.733)**	**(22.671.251.480)**	**199.108.290.663**

21c. *Overdue borrowings and financial lease liabilities*

The Company has no overdue borrowings and financial lease liabilities.

22. Bonus and welfare fund

	Beginning balance	Increase due to appropriation for profit	Disbursement during the year	Ending balance
Bonus fund	10.907.313.595	1.040.828.752	(11.202.548.675)	745.593.672
Welfare Fund	696.367.089	-	(40.000.000)	656.367.089
Bonus fund to Board of Directors and Supervisory Board	-	759.195.540	(759.195.540)	-
Total	**11.603.680.684**	**1.800.024.292**	**(12.001.744.215)**	**1.401.960.761**

23. Owner's equity

23a. Statement of changes in owner's equity

Information on changes in owner's equity is presented in the attached Appendix 04.

23b. Details of owner's capital

	Ending balance	Beginning balance
Imexpharm Pharmaceutical Joint Stock Company	103.486.110.000	80.346.370.000
Mr. Pham Uyen Nguyen	49.142.970.000	38.154.500.000
Mr. Nguyen Van Kha	40.590.730.000	33.959.460.000
Other shareholders	164.884.400.000	113.692.350.000
Total	**358.104.210.000**	**266.152.680.000**

During the period, the Company issued shares to pay dividends to existing shareholders at a ratio of 25:03 (existing shareholders holding 25 shares received 03 additional shares issued) in accordance with Resolution No. 01/NQ-AGP.The Annual General Meeting of Shareholders held on 27 March 2026. On this basis, the Company recognised an increase in Owner's equity and a decrease in retained profit/accumulated loss of VND 36.724.860.000. At the same time, the Company issued 3.992.290 shares under a public rights issue to existing shareholders to raise working capital, in accordance with General Shareholders' Meeting Resolution No. 02/NQ-AGP.The Annual General Meeting held on 25 August 2025 and the issue of 1.530.377 ordinary shares under the Employee Share Option Plan (ESOP) to supplement working capital, in accordance with Resolution No. 01/NQ-AGP.The Annual General Meeting of Shareholders held on 27 March 2026 increased Owner's capital and share premiums by VND 55.226.670.000 and VND 71.544.766.000 (after deducting costs directly related to the share issue incurred up to the reporting date, amounting to VND 582.600.000). On 21 June 2026, the Company received the 22nd amended Business Registration Certificate issued by the An Giang Provincial Department of Finance regarding the increase in authorised capital to VND 358.104.210.000, and the Company received Decision No. 993/QĐ-SGDHN dated 23 July 2026 from the Hanoi Stock Exchange approving the change to the trading registration of Agimexpharm Pharmaceutical Joint Stock Company's shares.

23c. Shares

	Ending balance	Beginning balance
Number of shares registered to be issued	35.810.421	26.615.268
Number of shares sold to the public	35.810.421	26.615.268
- *Common shares*	*35.810.421*	*26.615.268*
- *Preferred shares*	-	-
Number of shares repurchased	-	-
- *Common shares*	-	-
- *Preferred shares*	-	-
Number of outstanding shares	35.810.421	26.615.268
- *Common shares*	*35.810.421*	*26.615.268*
- *Preferred shares*	-	-

Par value per outstanding share: VND 10.000.

23d. *Profit distribution*

During the period, the Company distributed its 2025 profits in accordance with Resolution No. 01/NQ-AGP.ĐHĐCĐ dated 27 March 2026 of the 2026 Annual General Meeting of Shareholders, as follows:

		VND
• Dividend distribution in the form of shares (70,58% of profit after tax for 2025)	:	36.729.060.000
• Appropriation for bonus and welfare fund (2% of profit after tax for 2025)	:	1.040.828.752
• Appropriation for bonus fund to the Board of Directors and the Supervisory Board (1,46% of profit after tax for 2025)	:	759.195.540
• Appropriation to the investment and development fund (25,96% of profit after tax for 2025)	:	13.512.353.321

During the period, the Company paid dividends to shareholders as follows:

	Accumulated from the beginning	
	Current year	**Previous year**
Dividends from the previous year	-	11.343.723.000
Total	**-**	**11.343.723.000**

24. Off-Interim Financial Statements

24a. *Assets under operating lease*

The total minimum lease payments in the future for non-cancellable leasing contracts are classified by terms as follows:

	Ending balance	**Beginning balance**
Up to 1 year	705.996.288	705.996.288
More than 1 year to 5 years	2.823.985.152	2.823.985.152
Over 5 years	17.365.652.721	17.715.749.511
Total	**20.895.634.161**	**21.245.730.951**

The above operating lease payments comprise:

- The total land rental for 208 m² at No. 151, Dinh Tien Hoang Street, Long Xuyen Ward, An Giang Province, is VND 259.200 m²/year. The lease agreement was signed for a term of 50 years from 27 October 2005.
- The total land rental for 2.636 m² at No. 27, Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, is VND 1.036.800m²/year. The lease was signed for a term of 50 years from 19 December 2005.
- The total land rental for 57 m² at No. 01, Phan Dinh Phung Street, Long Xuyen Ward, An Giang Province, at a rental rate of VND 604.800 m²/year. The lease agreement was signed for a term of 50 years from 19 December 2005.
- The total land rental for 3.023 m² of land in My Thoi Ward, An Giang Province, at a rate of VND 72.000 m²/year. The lease was signed for a term of 50 years from 21 December 2006.
- Total land rental for 132,7 m² of land in My Thoi Ward, An Giang Province, at a rate of VND 25.920 m²/year. The lease was signed for a term of 50 years from 07 November 2017.

24b. Pledged and mortgaged assets

	Carrying values			
	Ending balance	**Beginning balance**	**Term of pledge or mortgage**	**Pledgee or mortgagee**
Short-term held-to-maturity investments – Term deposits (see Note V.2b)	5.000.000.000	5.000.000.000	By loan term	- Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch
Trade receivables (see Note V.3)	107.000.000.000	107.000.000.000	By loan term	- Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch; - Vietnam Technological and Commercial Joint Stock Bank (Techcombank) – Cho Lon Branch
Inventories (see Note V.7)	255.000.000.000	255.000.000.000	By loan term	- Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch - Joint Stock Commercial Bank for Foreign Trade of Vietnam (Vietcombank) – An Giang Branch - Vietnam Technological and Commercial Joint Stock Bank (Techcombank) – Cho Lon Branch
Tangible fixed assets (see Note V.10)	267.411.912.452	272.574.308.705	By loan term	- Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch - Joint Stock Commercial Bank for Foreign Trade of Vietnam (Vietcombank) – An Giang Branch
Intangible fixed assets (see Note V.12)	18.129.841.371	18.148.429.893	By loan term	- Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch - Prosperity and Growth Commercial Joint Stock Bank – An Giang Branch - Joint Stock Commercial Bank for Foreign Trade of Vietnam (Vietcombank) – An Giang Branch
Total	**652.541.753.823**	**657.722.738.598**		

24c. Foreign currencies

At the end of the accounting period, cash and cash equivalents include USD 64.929,01 (beginning balance: USD 26.528,45).

VI. SUPPLEMENTARY INFORMATION ON ITEMS PRESENTED IN THE INTERIM INCOME STATEMENT

1. Revenue from sales of goods and provisions of services

1a. Gross revenue

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Revenue from sales of merchandise	3.600.061.402	2.046.847.470
Revenue from sales of finished goods	450.479.421.771	407.736.216.867
Total	**454.079.483.173**	**409.783.064.337**

1b. Revenue from sales of goods and provisions of services to related parties

Transactions relating to the sale of goods and provision of services to related parties are presented in Note No. VII.1b.

2. Revenue deductions

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Trade discounts	-	1.115.668.282
Sales returns	2.453.068.792	726.372.960
Sales allowances	12.704.880	15.582.789
Total	**2.465.773.672**	**1.857.624.031**

3. Cost of sales

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Cost of merchandise sold	3.325.619.648	1.529.706.848
Costs of finished goods sold	318.466.179.486	290.222.412.143
Total	**321.791.799.134**	**291.752.118.991**

4. Financial income

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Demand deposit interest	32.654.566	15.282.887
Term deposit interest	434.013.700	103.561.644
Dividends and profit received	-	2.374.500
Exchange gain arising	143.507.811	120.399.214
Exchange gain due to the revaluation of monetary items in foreign currencies	115.794.094	-
Other financial income	-	32.735.363
Total	**725.970.171**	**274.353.608**

5. Financial expenses

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Borrowing costs	22.442.071.211	18.880.133.246
In which: Interest expense on financial assets	*1.979.464.355*	*971.484.825*
Exchange loss arising	88.040.237	334.192.210
Cash discount given to customers	971.484.825	1.311.260.939
Exchange loss due to the revaluation of monetary items in foreign currencies	-	330.989.924
Total	**23.501.596.273**	**20.856.576.319**

6. Selling expenses

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Expenses for employees	6.502.390.906	7.061.096.114
Tools, supplies	51.584.580	151.320.105
Depreciation/(amortization) of fixed assets	1.505.653.648	1.319.937.644
Expenses for external services	37.935.249.907	34.659.708.260
- Expenses for Commission, discount, promotion, advertisement	*33.650.351.484*	*31.471.886.851*
- Expenses for external services	*4.284.898.423*	*3.187.821.409*
Other expenses	5.205.988.046	3.722.071.135
Total	**51.200.867.087**	**46.914.133.258**

7. General and administrative expenses

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Expenses for employees	14.041.437.093	11.928.455.645
Office supplies	1.834.019.674	1.855.910.446
Depreciation/(amortization) of fixed assets	321.915.104	474.650.822
Taxes, fees and legal fees	141.649.258	57.200.126
Allowance for doubtful debts	395.354.064	277.861.521
Expenses for external services	3.628.711.771	3.612.404.457
Other expenses	3.492.600.833	3.271.706.268
Total	**23.855.687.797**	**21.478.189.285**

8. Other income

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Gain on liquidation, disposal of fixed assets	50.000.000	2.769.892.748
Collection of fees for testing, storage	160.237.182	203.377.764
Other income	10.584.000	185.416.121
Total	**220.821.182**	**3.158.686.633**

9. Earnings per share

9a. Basic/diluted earnings per share

	Accumulated from the beginning	
	Current year	**Previous year**
Accounting profit after corporate income tax	25.738.877.815	24.450.471.725
Appropriation for bonus and welfare fund (*)	(514.777.556)	(1.833.785.379)
Appropriation for bonus for the Board of Directors and the Supervisory Board (*)	(375.787.616)	(364.312.029)
Profit used to calculate basic/diluted earnings per share	24.848.312.643	22.252.374.317
The weighted average number of ordinary shares outstanding during the year	33.713.361	29.374.854
Basic/diluted earnings per share	**737**	**758**

(*) Bonus and welfare funds and bonus for the Board of Directors, the Supervisory Board in the current period are temporarily appropriated at the rate as stipulated in Resolution No. 01/NQ-AGP.ĐHĐCĐ dated 27 March 2026 of the 2026 Annual General Meeting of Shareholders.

9b. Other information

On 21 June 2026, the Company increased its charter capital from retained earnings. Basic/diluted earnings per share for the previous period have been adjusted to reflect this event. This adjustment causes a decrease in basic/diluted earnings per share of the previous year from VND 866 to VND 758.

10. Operating costs by factors

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Cost of merchandise sold	3.325.619.648	1.529.706.848
Materials and supplies	271.696.212.662	252.140.994.954
Labor costs	42.449.736.119	36.502.152.009
Depreciation/(amortization) of fixed assets	18.407.554.185	18.433.774.920
Expenses for external services	48.129.405.266	43.169.673.905
Other expenses	12.839.826.138	8.368.138.898
Total	**396.848.354.018**	**360.144.441.534**

VII. OTHER DISCLOSURES

1. Transactions and balances with related parties

The Company's related parties include the key management personnel, their related individuals and other related parties.

1a. Transactions and balances with the key management personnel and their related individuals

The Company's key management personnel include the Board of Directors, the Supervisory Board and the Board of Management. The key management personnel's related individuals are their close family members.

Transactions with the key management personnel and their related individuals

The Company has no sales of goods and service provisions to the key management personnel and their related individuals and only has following transactions with the key management personnel:

	Accumulated from the beginning of the year	
	Current year	**Previous year**
Collection of capital contribution (dividend payment in fomr of shares)	11.044.700.000	7.357.380.000
Dividend payment in cash	-	3.678.699.000
Advance payment	24.004.956.040	12.748.602.349
Reimbursement of advance payments	14.047.273.331	13.277.388.321

Guarantee commitments

The Company's key management personnel use their own term savings books as collateral for the Company's bank borrowings (see Note V.21a).

Receivables from and payables to the key management personnel and their related individuals

Receivables from and payables to the key management personnel and their related individuals are presented in Note No. V.5a.

Remuneration of the key management personnel

		Accumulated from the beginning	
Full name	**Position**	**Current year**	**Previous year**
Ms. Pham Thi Bich Thuy	Chairwoman cum Deputy General Director	250.694.900	218.940.950
Mr. Nguyen Van Kha	Vice Chairman cum General Director	386.000.000	394.000.000
Mr. Huynh Hoang Ha	Board Member cum Deputy General Director	237.501.375	229.479.880
Ms. Tran Thi Dao	Board Member	128.000.000	105.000.000
Mr. Nguyen Quoc Dinh	Board Member	128.000.000	105.000.000
Mr. Pham Uyen Nguyen	Board Member	128.000.000	105.000.000
Mr. Lam Tri Hien	Deputy General Director	75.449.315	64.642.240
Mr. Vu Minh Tuan	Deputy General Director	72.083.845	82.639.411
Mr. Le Van Mac	Deputy General Director (appointed on 25 May 2026)	155.149.600	-
Ms. Tran Thi Thanh Hang	Chief of the Supervisory Board	126.000.000	104.000.000
Ms. Pham Hai Yen	Supervisory Board Member (resigned on 27 March 2026)	-	15.303.360
Ms. Nguyen Hong Ngoc	Supervisory Board Member	27.000.000	18.000.000
Ms. Nguyen Thi An	Supervisory Board Member (appointed on 27 March 2026)	41.082.261	-
Total		**1.754.961.296**	**1.442.005.841**

1b. Transactions and balances with other related parties

Other related parties of the Company include:

Other related parties	Relationship
Imexpharm Corporation	Major shareholder (holding 28,90% of charter capital)
USA-AGP Pharma, LLC	Joint ventures
Lien Phat Vung Tau Joint Stock Company	Major shareholder (holding 6,89% of charter capital)
STA-X Pharmaceutical Joint Stock Company	A company whose founding shareholder is a member of the Board of Directors and Deputy General Director of the company

Transactions with other related parties

The Company has entered into transactions relating to the sale of goods and the provision of services, as well as other transactions, with other related parties as follows:

	Accumulated from the beginning	
	Current year	**Previous year**
Imexpharm Corporation		
Revenue from sales of goods and provisions of services	10.532.044.940	12.380.518.618
Purchases of merchandise	4.806.213.197	10.412.468.510
Storage fee	81.818.182	163.636.364
Collection of capital contribution in form of dividend payment in share	11.087.790.000	7.304.210.000
Dividend distribution in cash	-	3.652.108.000
USA-AGP Pharma, LLC		
Revenue from sales of goods	-	716.327.070

The prices of merchandises supplied to other related parties are market prices. The purchases of merchandises from other related parties are done at the agreed prices.

Receivables from and payables to other related parties

The receivables from and payables to other related parties are presented in Notes No. V.3 and V.14.

The receivables from other related parties are unsecured and will be paid in cash. There are no allowances for doubtful debts made for the receivables from other related parties.

2. Segment information

Segment information is presented based on business segments and geographical segments. Segment reporting is mainly done on the basis of business segments since the Company's business operations are organized and managed on the basis of the natures of its products.

2a. Information on business segment

Principal business activity of the Company is to trade finished medicines of all kinds. Additionally, other business activity of the Company is mainly sale of goods and materials. Sales from other business activity only account for a very small proportion of gross sales (approximately 0,79% of gross sales for the first six months of 2026). Sales and costs of business activities are presented in Notes No. VI.1a and VI.3.

2b. Information on geographical segment

The Company's operations include exports and local sales.

Details of net external revenue in respect of geographical segment based on the location of customers are as follows:

	Accumulated from the beginning	
	Current year	**Previous year**
Domestic	444.754.915.310	403.919.490.514
Overseas	6.858.794.191	4.005.949.792
Total	**451.613.709.501**	**407.925.440.306**

3. Comparative figures

3a. Adoption of the new accounting system

For the fiscal year ended 31 December 2026, the Company has applied the Corporate Accounting Standards under Circular 99, replacing Circular 200/2014/TT-BTC dated 22 December 2014.

The transition to the application of Circular 99 is carried out using the following methods:

- For changes in accounting policies where the Circular 99 provides specific transition guidance, the Company follows that guidance.
- For changes in accounting policies where the Circular 99 does not require retroactive adjustments or simplified retroactive adjustments, the Company applies the non-retroactive method.

Circular 99 does not provide specific transition guidance for the following changes. Consequently, the Company applies the non-retrospective method to Payables for dividends and profit distributions.

3b. Impact of changes in accounting policies

The impact of changes in accounting policies on comparative figures in the Interim Financial Statements is as follows:

	Code	Previous figures Adjusted	Adjustment due to changes in accounting policies	Figures after adjustment	Notes
Interim Financial Statements					
Cash	111	125.493.642.022	(98.404.390.567)	27.089.251.455	(i)
Cash equivalents	112	45.985.764.870	2.645.756	45.988.410.626	(ii)
Short-term held-to-maturity investments	123	5.000.000.000	88.027.397	5.088.027.397	(ii)
Other short-term receivables	135	79.105.856.579	(90.673.153)	79.015.183.426	(ii)
Other current assets	165	-	98.404.390.567	98.404.390.567	(i)

(i) This is an amount that has been frozen for the purpose of receiving proceeds from the public offering of additional shares to existing shareholders at Vietnam Joint Stock Commercial Bank of Industry and Trade (VietinBank) – An Giang Branch as at 31 December 2025.

(ii) Adjustments include:

- Cash equivalents: an increase due to the reclassification of accrued Term deposit interest.
- Short-term held-to-maturity investments: increase due to the reclassification of Term deposit interest.
- Other short-term receivables: decrease due to the reclassification of Term deposit interest.

4. Significant accounting judgements, estimates and assumptions

In preparing the Interim Financial Statements, the Board of Management has made assumptions and estimates that affect the figures for assets, liabilities, revenue and expenses. Actual results may differ from these estimates. The Board of Management assesses and updates these significant accounting judgements, estimates and assumptions on an ongoing basis based on historical experience and other relevant factors.

The estimates described below have been identified by the Board of Management as those that could have a material effect on the Financial Statements for the subsequent financial year should the underlying assumptions change.

Allowance for doubtful debts

The Company estimates the allowance for doubtful debts based on an assessment of the recoverability of individual receivable balances, taking into account debt ages, customers' financial condition. Uncertainty arises from forecasting customers' future ability to pay, particularly in a volatile economic environment.

As at 30 June 2026, the total balance of trade receivables was VND 184.318.875.914, of which the Company had recognised a provision of VND 4.996.072.937.

The Board of Management assesses the likelihood of actual losses exceeding the provisions set aside as low, based on customers' payment history and available information regarding the financial situation of each debtor.

To mitigate credit risk, the Board of Management has implemented the following measures:

- Performing regular monitoring and collection of outstanding receivables;
- Requiring collateral or third-party guarantees for significant credit exposures;
- Reviewing customer credit limits on a quarterly basis; and
- Initiating legal proceedings or other legal enforcement actions against overdue receivables where appropriate.

Allowance for devaluation of inventories

The Company estimates the net realizable value of inventories based on estimated selling prices less estimated selling expenses. Uncertainty arises from fluctuations in market prices, changes in customer demand and the risk of merchandise becoming obsolete.

Based on market conditions at the reporting date, including market price trends over the preceding six months and sales contracts executed, the Board of Management considers the likelihood that actual selling prices will be significantly lower than the estimated amounts to be low.

Based on the assessment performed as at 30 June 2026, the Board of Management concluded that the net realizable value of inventories is not lower than their cost. Accordingly, no allowance for devaluation of inventories is required.

This assessment will continue to be reviewed at each subsequent reporting date.

To minimize risks, the Board of Management has implemented the following measures:

- Conducting physical inventory counts and quality assessments every six months;
- Adjusting production plans in line with market demand;
- Implementing promotional programs to accelerate the sale of slow-moving inventories; and
- Diversifying distribution channels to expand market coverage.

Estimated useful lives and residual values of fixed assets

The Company estimates the useful lives of fixed assets based on technical assessments and actual operating experience Uncertainty arises from technological developments, changes in utilization patterns and maintenance conditions that may differ from the original assumptions, resulting in actual useful lives being shorter or longer than initially estimated.

The Board of Management considers the likelihood of significant differences between the estimated and actual useful lives to be low for the majority of the Company's fixed assets.

As of 30 June 2026, the Board of Management has not identified any factors that would require significant revisions to the assumptions currently applied in determining the useful lives of fixed assets.

The Board of Management has adopted the following measures:

- Reviewing and, where appropriate, revising estimated useful lives on an annual basis;
- Performing scheduled maintenance in accordance with technical requirements;
- Assessing assets for indicators of impairment at each reporting date in accordance with applicable accounting standards; and
- Planning timely replacement of assets to minimize disruptions to business operations.

Estimation of corporate income tax and deferred tax

The determination of income tax expense and deferred tax assets/tax liabilities require the Board of Management to exercise judgement regarding the application of prevailing tax regulations, the probability of generating sufficient future taxable profits against which deferred tax assets can be utilized, and the potential outcomes of tax audits and assessments by the tax authorities.

Based on the Company's recent operating performance and the approved business plan, the Board of Management considers the likelihood that actual future taxable profits will be significantly lower than forecast to be low.

The Board of Management has adopted the following measures:

- Reviewing the recoverability of deferred tax assets on an annual basis;
- Consulting tax specialists regarding the application of tax regulations to complex transactions;
- Prepare a complete set of supporting documents to be ready for a tax audit.
- Closely monitoring developments in tax legislation and updating tax estimates, where necessary, on a timely basis.

5. Subsequent events

From the end of the accounting period to the approval date of the Financial Statements, there are no material events which are required adjustments or disclosures in the Interim Financial Statements.

Approved on 12 August 2026

CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM

Do Thi Kim Len	Pham Do Phuong Thao	Nguyen Van Kha
Preparer	Acting Chief Accountant	Legal Representative

Appendix 01: Increases and decreases in tangible fixed assets

Unit: VND

	Buildings and structures	Machinery and equipment	Vehicles and transmission equipment	Office equipment and management tools	Total
Historical costs					
Beginning balance	345.741.809.657	137.857.621.152	14.744.430.215	4.084.788.450	502.428.649.474
Acquisition during the period	184.970.390	5.299.947.088	1.193.188.556	185.000.000	6.863.106.034
Completed constructions	323.087.037	22.862.544.233	-	-	23.185.631.270
Liquidation and disposal	-	(23.548.918.239)	(740.000.000)	-	(24.288.918.239)
Ending balance	**346.249.867.084**	**142.471.194.234**	**15.197.618.771**	**4.269.788.450**	**508.188.468.539**
In which:					
Assets fully depreciated but still in use	18.788.153.469	34.969.004.457	8.468.258.758	1.136.544.154	63.361.960.838
Assets waiting for liquidation	-	-	-	-	-
Accumulated depreciation					
Beginning balance	67.755.202.311	99.370.934.928	11.665.538.628	1.787.578.246	180.579.254.113
Depreciation during the period	7.635.762.161	4.734.614.959	485.872.238	255.356.008	13.111.605.366
Liquidation and disposal	-	(616.954.356)	(740.000.000)	-	(1.356.954.356)
Ending balance	**75.390.964.472**	**103.488.595.531**	**11.411.410.866**	**2.042.934.254**	**192.333.905.123**
Carrying value					
Beginning balance	277.986.607.346	38.486.686.224	3.078.891.587	2.297.210.204	321.849.395.361
Ending balance	**270.858.902.612**	**38.982.598.703**	**3.786.207.905**	**2.226.854.196**	**315.854.563.416**
In which:					
Assets temporarily not in use	-	-	-	-	-
Assets waiting for liquidation	-	-	-	-	-

Approved, 12 August 2026

M.S.D.N: 1600699279 ★ CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM ★ T.P LONG XUYÊN-T.AN GIANG

Do Thi Kim Len
Preparer

Pham Do Phuong Thao
Acting Chief Accountant

Nguyen Van Kha
Legal Representative

Appendix 02: Increases and decreases in construction in progress

Unit: VND

	Beginning balance	Increase during the period	Inclusion into fixed assets during the period	Transfer to long-term prepaid expenses	Ending balance
Acquisition of fixed assets	9.800.000.000	-	-	-	9.800.000.000
Construction in progress	115.638.110.860	110.502.529.447	(23.185.631.270)	(31.677.800)	202.923.331.237
- Liquid Medicine Factory construction project	*75.967.225.964*	*4.398.901.110*	-	-	*80.366.127.074*
- Air filtration system of the Liquid Medicine Factory – Binh Hoa	*11.871.037.947*	*2.709.704.200*	*(14.580.742.147)*	-	-
- Expansion project of the Medicinal Plant Factory	*17.737.827.916*	*14.013.241.852*	-	-	*31.751.069.768*
- Liquid medicine production machinery line project	-	*79.427.424.679*	-	-	*79.427.424.679*
- Other constructions	*10.062.019.033*	*9.953.257.606*	*(8.604.889.123)*	*(31.677.800)*	*11.378.709.716*
Total	**125.438.110.860**	**110.502.529.447**	**(23.185.631.270)**	**(31.677.800)**	**212.723.331.237**

Approved, 12 August 2026

CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM

Do Thi Kim Len	**Pham Do Phuong Thao**	**Nguyen Van Kha**
Preparer	**Acting Chief Accountant**	**Legal Representative**

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam
INTERIM FINANCIAL STATEMENTS
For the first 6 months of the fiscal year ending 31 December 2026

Appendix 03: Changes in taxes and other obligations to the State Budget

Unit: VND

	Beginning balance		Increase during the period		Ending balance	
	Payables	Receivables	Amount payable	Amount paid	Payables	Receivables
Export-import duties	-	-	37.671.840	(59.314.568)	-	21.642.728
Corporate income tax	13.578.767.542	-	6.471.672.748	(14.202.643.939)	5.847.796.351	-
Personal income tax	-	167.552.491	3.342.070.015	(3.459.985.467)	-	285.467.943
Property tax	-	-	450.000	(450.000)	-	-
Land rental	-	-	141.199.258	(141.199.258)	-	-
Total	**13.578.767.542**	**167.552.491**	**9.993.063.861**	**(17.863.593.232)**	**5.847.796.351**	**307.110.671**

Approved, 12 August 2026

M.S.D.N: 1600699... CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM T.P LONG XUYÊN-T.AN GIANG

Do Thi Kim Len
Preparer

Pham Do Phuong Thao
Acting Chief Accountant

Nguyen Van Kha
Legal Representative

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An, Giang Province, Vietnam
INTERIM FINANCIAL STATEMENTS
For the first 6 months of the fiscal year ending 31 December 2026
Appendix 04: Statement of changes in owner's equity

Unit: VND

	Owner's capital	Share premiums	Investment and development fund	Retained earnings	Total
Beginning balance of the previous year	231.439.410.000	25.726.714.700	93.803.543.069	48.889.738.710	399.859.406.479
Payment of dividends in the form of shares in the previous period	23.141.300.000	-	-	(23.141.300.000)	-
Issuance of shares for cash in the previous period	11.571.970.000	9.257.576.000	-	-	20.829.546.000
Profit in the previous period	-	-	-	24.450.471.725	24.450.471.725
Appropriation to funds in the previous period	-	-	9.777.947.742	(14.173.827.210)	(4.395.879.468)
Dividends and profit distributions in the previous period	-	-	-	(11.571.970.500)	(11.571.970.500)
Disbursements from funds in the previous period	-	-	(33.206.628)	-	(33.206.628)
Transfer of fractional shares from share dividends to the investment and development fund	-	-	2.641.000	(2.641.000)	-
Ending balance of the previous period	**266.152.680.000**	**34.984.290.700**	**103.550.925.183**	**24.450.471.725**	**429.138.367.608**
Beginning balance of the current year	266.152.680.000	34.984.290.700	101.242.219.168	52.041.437.613	454.420.627.481
Payment of dividends in the form of shares in the current period	36.724.860.000	-	-	(36.724.860.000)	-
Issuance of shares for cash in the current period	55.226.670.000	71.544.766.000	-	-	126.771.436.000
Profit in the current period	-	-	-	25.738.877.815	25.738.877.815
Appropriation to funds in the current period	-	-	13.512.353.321	(15.312.377.613)	(1.800.024.292)
Disbursements from funds in the current period	-	-	(390.582.183)	-	(390.582.183)
Transfer of fractional shares from share dividends to the investment and development fund	-	-	4.200.000	(4.200.000)	-
Ending balance of the current period	**358.104.210.000**	**106.529.056.700**	**114.368.190.306**	**25.738.877.815**	**604.740.334.821**

Approved, 12 August 2026

M.S.D.N: 16000... CÔNG TY CP DƯỢC PHẨM AGIMEXPHARM T.P LONG XUYÊN - T. AN GIANG

Do Thi Kim Len
Preparer

Pham Do Phuong Thao
Acting Chief Accountant

Nguyen Van Kha
Legal Representative